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i
Abstract
Chronic Myelogenous Leukemia (CML) is a blood cancer that arises when hematopoietic cells
acquire an abnormal protein known as BCR-ABL. Current therapies for CML include drugs that
inhibit BCR-ABL. However, these drugs only suppress the disease and do not cure it. One reason
is that BCR-ABL drugs fail to kill the primitive population of CML cells, referred to as leukemia
stem cells (LSCs), which are responsible for initiating and propagating CML. Since LSCs are not
killed, the cancer is not cured and many affected patients eventually relapse. Recent studies suggest
that LSCs are protected from current therapies by the bone marrow micro-environment where they
reside. There, cytokine signaling molecules are present, which mediate processes that protect LSCs
from BCR-ABL drugs. The stem cell factor (SCF) is one of these signaling molecules. It activates
the receptor c-Kit located on the surface of LSCs, and this activation in turn allows proliferating
LSCs to resist BCR-ABL drugs, even without prior exposure to these drugs, i.e., innate resistance
is observed.
In this thesis, the mechanism of this innate resistance is investigated, so that a suitable treat-
ment strategy can be developed. To this end, a co-agent approach based on synthetic antibodies
(sABs) is proposed to inhibit the receptor c-Kit, with the goal of disrupting its activation by the lig-
and SCF. This disruption should in turn block the SCF-mediated innate resistance, thus potentially
restoring BCR-ABL drug apoptotic activity. The method for this disruption involves targeting
the c-Kit structural susceptibility. Specifically, the sABs are designed via antibody phage display
technology to target the D1–D2–D3 domains representing the SCF binding sites, hence prevent-
ing downstream pathway activation. The hypothesis is that, by blocking the SCF-mediated innate
resistance, a suitable combination of such an sAB co-agent and a BCR-ABL drug should be con-
ducive to suppressing LSCs, thereby providing a potential means to improve CML treatment.
In addition, to assess the performance of the proposed treatment strategy, a set of in vitro tests
is conducted, focusing on performance behaviors such as cell binding, cell death, and the progen-
itor inhibition. The experimental results support the hypothesis that the proposed combinatorial
strategy is indeed a promising approach to mitigate the innate resistance, thus restoring BCR-ABL
drug apoptotic activity.
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1. Introduction
The overarching objective of this thesis is to explore the challenge of innate resistance in
chronic myelogenous leukemia (CML), so that a novel treatment based on synthetic antibodies
(sABs) can be developed accordingly.
1.1 Thesis Background
CML is a cancer of the hematopoietic system that is initiated by an abnormal breakpoint cluster
region–Abelson (BCR-ABL) fusion gene [1–4]. Because of its highly consistent genetic abnormal-
ity and qualitatively different fusion gene product, CML remains a prime example for the devel-
opment of selective treatment, even promisingly as a paradigm of curative strategies [5,6]. In fact,
exploiting the consistent genetic characterization of CML, the first generation BCR-ABL inhibitor
imatinib has achieved notable success. In clinical applications, imatinib has been the mainstay
of first-line therapy, even though later-generation drugs have been developed to address known
shortcomings, including potency and drug resistance, of imatinib [7, 8]. For instance, the second-
generation nilotinib should only be contemplated once imatinib resistance is observed. However,
recent evidence suggests that second-generation drugs may in fact be considered for first-line de-
fense, effectively supplanting imatinib completely [9–12]. The rationale is that the initial treatment
is highly indicative of the overall therapeutic effectiveness. Specifically, patients not achieving a
complete cytogenetic response by 12 months have an increased risk of disease progression, while
those achieving an early major molecular response have a very low probability of disease progres-
sion [9]. The results suggest that CML treatments may be improved with more potent BCR-ABL
inhibition, e.g., using second-generation drugs, during initial therapy. In either case, whether used
as a second-line or first-line defense therapy, second-generation drugs such as nilotinib are clearly
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becoming important research focus for improving CML treatments.
While more potent than first-generation drugs and effective against various imatinib-resistant
CMLs, second-generation drugs also have fundamental challenges, including the problem of drug
resistance and relapse. In particular, the drugs may suffer from an innate resistance challenge,
which means that the drugs have reduced activity against CML with no prior exposure [13, 14].
Furthermore, most existing drugs do not address this challenge, which may lead to treatment fail-
ure. Therefore, this thesis investigates strategies to overcome the innate resistance challenge, in
order to improve CML treatment.
To this end, the focus of this thesis is mainly on the drug nilotinib. Compared to imatinib,
this second-generation drug offers a number of advantages. Specifically, imatinib is characterized
by low potency (requiring micromolar range), as well as by the inability to completely eradicate
BCR-ABL+ hematopoietic stem cells. Therefore, imatinib suffers from drug resistance, leading
to disease relapse. Resistance to imatinib in CML may be due to innate resistance, or to acquired
resistance, where the tumor initially responds to imatinib but becomes resistant over time [15–
17]. In response to these shortcomings of imatinib, nilotinib was developed [1, 14]. Nilotinib
offers higher potency relative to imatinib, and is active against most imatinib-resistant BCR-ABL
mutants. In other words, nilotinib is a promising drug in effectively addressing acquired imatinib
resistance. However, nilotinib still does not overcome the problem of innate resistance. As such,
nilotinib may also be ineffective for patients exhibiting imatinib resistance without prior exposure
to this drug, since the mechanism of this innate resistance may not be dependent on BCR-ABL. It
is this type of resistance that the thesis seeks to mitigate.
1.2 Combinatorial Strategy to Reduce Innate Resistance
One significant class of mechanism responsible for innate resistance is due to cytokine medi-
ated signaling, which is implicated in the protection of leukemia stem cells (LSCs) against BCR-
ABL inhibitors [13, 18, 19]. LSCs, a primitive population of cancer stem cells that reside and
survive long term in the bone marrow (BM) endosteal niche, are known to be important target for
leukemia treatment, and eliminating the quiescent LSCs should be critical for developing potential
curative strategies [20,21]. One promising direction for suppressing LSCs is to block the cytokine
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signaling pathways so as to induce apoptosis, since these pathways provide protection mechanisms
for these proliferating LSCs [22, 23]. Specifically in CML, a pathway protecting LSCs is medi-
ated by the stem cell factor (SCF), which activates its receptor c-Kit present on LSCs [24, 25].
Therefore, to restore the apoptotic activities of BCR-ABL inhibitors, the c-Kit pathway must be
inhibited [26, 27].
To this end, the strategy to be proposed should achieve the following properties to be an ef-
ficient solution. First, it should specifically target the c-Kit pathway with high affinity sABs in
order to enhance potency and minimize possible side effects. Moreover, the synthetic antibody de-
sign process should flexibly allow for incorporation of c-Kit configuration information. Lastly, the
antibody production process should be cost effective, allowing for efficient mass production and
rapid optimization to derive the suitable candidates, since a massive number of receptor molecules
may need to be inhibited to block the pathway. An emerging design paradigm immensely con-
ducive to achieving these desired properties is based on the antibody display technology to gen-
erate sABs [28–30]. It should be noted that, in the context of CML therapy, it is not sufficient to
solve the innate resistance alone — the original CML disease still needs to be addressed. In other
words, these sABs need to be applied as co-agents in a combination with a suitable BCR-ABL
drug. Therefore, the solution to be developed in this thesis involves an investigation of both sAB
production and combinatorial therapy strategy.
1.3 Thesis Organization
The remainder of this thesis is organized as follows. Chapter 2 provides a focused literature
survey on CML and existing therapies, in order to formulate the research problem and hypothesis
in Chapter 3. Chapter 4 describes experimental materials, equipment, and protocols utilized for
all preparation steps and tissue culture assays in this work. The proposed research methodology is
described in Chapters 5 and 6, respectively on the combinatorial strategy, and the corresponding
test strategy with experimental findings. Lastly, Chapter 7 summarizes the thesis and outlines
directions for future research.
3
2. Literature Survey: CML Overview and Existing
Therapies
This chapter reviews the CML literature with a focus on existing therapies and the problem of
innate resistance.
2.1 CML Overview
CML is a cancer disease of hematopoietic stem cells with hyperproliferation of often immature
cells of the myeloid, megakaryocytic and erythroid lineages. It exhibits a mainly biphasic char-
acterization: an initially chronic phase (CP) progressing to a treatment-resistant blast crisis (BC).
Symptoms of CML patients include night sweats, fatigue, abdominal fullness, gout, leukocytosis,
and splenomegaly. Most often, the disease occurs in adults, where the median age at diagnosis is
50 to 55 years [14, 31]. The exact causes are generally indeterminate, but it may be found after
exposure to high doses of ionizing radiation. CML may initially linger with unspecific symptoms
over three to five years (i.e., CP of the disease), but without proper therapy, the disease likely pro-
gresses to an accelerated phase, characterized by an increase in disease burden and the occurrence
of leukemic stem cells (LSCs). Finally, if still unchecked, the disease progress exacerbates, rapidly
leading into blast crisis with highly aberrant leukemic cells and lethality within months [14,32,33].
Epidemiologically, CML is actually not a pervasive cancer, with a modest annual incidence of
1.5/105 [1]. Nevertheless, it is a clinically significant disease, due to its profound impact on the
development of evidence-based medicine, as well as on cancer cytogenetics and therapy [34, 35].
In fact, historically, CML was the first human cancer to be consistently associated with a genetic
abnormality, namely the Philadelphia (Ph) chromosome t(9;22) (q34;q11). Furthermore, the fusion
protein BCR-ABL, encoded by the Ph chromosome, illustrated in Figure 2.1, was discovered to be
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the etiological determinant of CML. Subsequently, detailed knowledge of BCR-ABL structure was
unraveled as a subset of the tyrosine kinase family, thus facilitating suitable therapy development.
In other words, this discovery in CML disease characterization changed the landscape of general
cancer research, and laid the foundation for the field of targeted anticancer therapy [36, 37].
Normal 
Chromosome  #9
Normal
Chromosome  #22
ABL
BCR
BCR-ABL
Changed  Chromosome  #9
Philadelphia Chromosome
ABL
BCR
(Translocation)
Figure 2.1: Schematic Diagram of the Philadelphia Chromosome as a Result of Reciprocal
Translocation. The ABL and BCR genes locate on the long arms of the chromosome 9 and
22, respectively. As a result of the reciprocal translocation, the Philadelphia chromosome forms,
which involves the ABL proto-oncogene on the chromosome 9 and BCR on the chromosome 22,
thus creating the BCR-ABL fusion gene.
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2.2 Early CML Therapies
The early therapeutics include spleen irradiation, hydroxycarbamide, and busulfan or interfe-
ron-alpha. These solutions are generally undesirable, since the involved cytotoxic agents target
malignant cells by modifying their DNA to inhibit the mechanics of cell division [6,38,39]. While
this approach achieved a notable degree of success in treating leukemias, lymphomas, and other
malignancies, it is also fundamentally flawed: these cytotoxic agents destroyed both malignant
and benign cells, often with adverse side-effects. Moreover, among the early therapeutics, only
interferon-alpha induced cytogenetic responses in around 20% of patients, and actually with only
partial responses (≤35% Ph-positive metaphases) [40–42]. In other words, even the most success-
ful solution of this era offered limited therapy, temporally prolonging survival, but only for selected
patients.
Instead, by exploiting biochemical knowledge of the cancer pathways, molecularly targeted
agents were developed, with the noteworthy advent of the BCR-ABL inhibitor imatinib mesylate
for CML treatment. Imatinib has revolutionized CP-CML treatment, by improving the 5-year
survival rates of CML patients from approximately 30% to 90–95% [1, 17, 36].
Imatinib mesylate is the first tyrosine kinase inhibitor (TKI), belonging to the 2-phenylamino-
pyrimidine (PAP) class of pharmacological compounds, approved for the treatment of multiple
cancers, most notably CML and gastrointestinal stromal tumor (GIST) [43–45]. Imatinib functions
as a specific competitive inhibitor that blocks the ATP binding of the ABL kinase domain in its
inactive conformation, thereby inhibiting the tyrosine kinase activity. Besides selectively inhibiting
all the ABL tyrosine kinases, including BCR-ABL and Abelson-related gene (Arg), imatinib is also
found to partially inhibit the kinase activity against the α- and β-platelet-derived growth factor–
receptors (PDGF-Rs) and SCF receptor [46–50].
2.3 Resistance Challenges with Existing CML Therapies
While the targeted small-molecule chemotherapeutics exhibit tremendous improvements com-
pared to the early therapeutics, they are still far from a panacea. Specifically, imatinib is char-
acterized by low potency (requiring micromolar range), as well as by the inability to completely
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eliminate proliferating LSCs. Therefore, relapse and drug resistance can be observed [51,52]. Re-
sistance to imatinib in CML may be due to innate resistance, i.e., without prior exposure to the
drug, or to acquired resistance, where the tumor initially responds to therapy but becomes resistant
over time. Multiple mechanisms of resistance to imatinib in CML have been defined [15–17, 44].
Importantly, it is found that bone marrow cytokine signaling is responsible for the mechanism of in-
nate resistance. And perhaps more startlingly, whether intrinsic or acquired, resistance is believed
to cause treatment failure in over 90% of patients treated with CML drugs [53, 54]. Examples of
imatinib resistance mechanisms include BCR-ABL–dependent mutations [43, 45, 48, 55, 56]:
1. Point mutations in the ABL kinase domain that directly impede imatinib binding;
2. BCR-ABL gene amplification and protein overexpression that allow for residual kinase ac-
tivity during or after imatinib therapy.
Despite the known challenge with resistance, imatinib currently remains a preferred solution in
treating many CML cases, at 400 mg daily as the initial treatment. Only when resistance occurs at
this dose, defined as either no response even at onset (i.e., innate resistance), or an eventual loss of
effectiveness (i.e., acquired resistance), then the clinician may adopt three possible options [40,57]:
1. dose increase to 600 or 800 mg daily;
2. replacement with another TKI;
3. allogeneic stem cell transplant if suitable conditions are met, e.g., young patients and an
availability of suitable stem cell donor.
However, these options have practical limitations and in fact, may not always be viable. For
instance, a response may not occur even with acceptable dose increase, i.e., a response only occurs
at a cytotoxic level of TKI, with unacceptable risk and adverse side effects [14]. This is particularly
relevant if innate resistance due to BCR-ABL–independent factors is the underlying cause, e.g.,
with the SCF-mediated resistance thwarting TKI effectiveness [58].
In response to the shortcomings of imatinib, several second-generation TKIs, including nilo-
tinib and dasatinib [1, 14, 59], were developed with improved affinity and specificity against the
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BCR-ABL kinase domain and most of the clinically relevant BCR-ABL mutants, except the T315I
gatekeeper mutant (which is addressed by the developing drug ponatinib [60,61]). While dasatinib
exhibits increased potency, it suffers from reduced selectivity with respect to certain BCR-ABL
mutations and also has a relatively short circulating half-life, thus limiting its applicability [62,63].
Structurally similar to imatinib, nilotinib is also a selective TKI that inhibits the activity of certain
tyrosine kinases, particularly with high potency against ABL as well as robustness against many
kinase domain mutations responsible for imatinib acquired resistance. This means that nilotinib
can be effective in treating CML cases with BCR-ABL-dependent imatinib resistance. However,
compared to imatinib, nilotinib demonstrates much lower potency in inhibiting the kinase activity
of the α- and β-PDGF-Rs and SCF receptor [64–67]. And as will be seen in the sequel, this SCF
receptor is implicated in innate resistance and also needs to be inhibited to effectively treat CML.
In other words, in cases with innate resistance due to BCR-ABL–independent mutations, nilotinib
may actually be less effective compared to imatinib, unless a co-agent is used to block the SCF
pathway, in turn restoring the nilotinib apoptotic activity.
Nevertheless, at least with respect to acquired imatinib resistance in treating CML, nilotinib
represents a promising replacement. However, nilotinib does not overcome the problem of innate
resistance due BCR-ABL-independent mechanisms, including those sustained by cytokine signal-
ing [65, 67]. In other words, for such cases, nilotinib may be incapable of completely eradicating
the minimal residual disease (MRD) due to the ineffectiveness against the primitive population of
quiescent LSCs, which reside in the bone marrow (BM) micro-environment to evade TKI treat-
ment [68–70]. This evasion is possible since the BM micro-environment provides a protective
sanctuary — via cytokine signaling — in which proliferating LSCs are resistant to the TKI-induced
apoptosis — prolonging their survival and acquiring other advantageous mutations — and thus sus-
taining MRD in CML patients [66, 71–73]. One such cytokine signaling pathway responsible for
protecting LSCs against BCR-ABL inhibitors is mediated by the SCF growth factor. Released by
the BM niche, this growth factor is a signaling molecule, which orchestrates the biological ac-
tivities of cells through intercellular communication, and its receptor is the c-Kit molecule, also
known as cluster of differentiation (CD) 117, located on the LSCs [25, 74–76].
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Biochemically c-Kit belongs to the tyrosine kinase family, and knowledge about its structure
can be found in the existing literature. In particular, specific epitopes related to susceptibility in
the c-Kit configuration have been identified [25, 77, 78]. As will be elaborated subsequently in
Chapter 5, treatment strategies will specifically target these epitopes located on the c-Kit molecule
in order to block the SCF-mediated pathway. In other words, the co-agents targeting these epitopes
will help mitigate innate resistance and, together with a BCR-ABL inhibitor such as nilotinib,
provide a suitable overall treatment against CML. This is a combinatorial approach which offers
synergistic potential for selectively targeting and suppressing proliferating LSCs, which are a cause
of innate resistance and a reservoir for CML relapse [5, 21].
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3. Hypothesis and Objectives
In this chapter, a recapitulation of limitations with existing CML therapies will first be pre-
sented, in order to formally define the problem addressed by this thesis. Then an overview of the
methodology for developing strategies to overcome innate resistance will be provided.
3.1 Limitations with Existing CML Therapies
As explored in Chapter 2, the challenge of interest is innate resistance, particularly as caused
by cytokine signaling. Most existing CML drugs focus on inhibiting the BCR-ABL oncogene
pathway. New drugs offer improvements with respect to potency and resistance of older drugs.
However, the resistance types addressed are mainly limited to those dependent on BCR-ABL mu-
tations. For example, most recently approved CML drugs, viz. bosutinib and ponatinib, still do not
have specific provisions against innate resistance to eradicate LSCs, and thus remain susceptible
to treatment failure [60, 79].
Furthermore, recent research findings indicate that innate resistance is best characterized as
multifactorial, which means that a combinatory approach is suitable for simultaneously address-
ing the different aspects involved [14]. In other words, a singleton solution with only one drug
is likely unable to simultaneously treat the causative factor of CML disease, as well as to miti-
gate innate resistance. On the other hand, to be efficient in treating innate resistance in CML, a
combinatory treatment needs to be strategically designed to fulfill suitable objectives, including
complementarity of the involved co-agents for overall synergy.
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In brief, with respect to the innate resistance problem in CML, limitations with existing thera-
pies mainly involve:
1. a deficiency in solutions targeting innate resistance, specifically with respect to cytokine
signaling mechanisms;
2. a lack of assessment results and research findings on combinatorial strategies especially with
novel co-agents such as sABs, to target the multifactorial problem described above.
Addressing the first limitation is tantamount to designing suitable co-agents, whereas tackling the
second limitation consists of selection and testing strategies to ensure efficiency and complemen-
tary properties of the constituents in the combinatorial therapy. These factors will be taken into
account in this research.
3.2 Hypothesis
In light of requirements established in the previous section, the following hypothesis is formu-
lated: a strategically designed combination of a nilotinib and a co-agent inhibiting the SCF/c-Kit
pathway should be effective in suppressing proliferating LSCs with innate resistance, thus provid-
ing a potential means to improve CML treatment.
As will be elaborated in Chapter 5, candidates for inhibitors will be designed based on sABs to
inhibit the c-Kit pathway responsible for innate resistance.
Visually, Figure 3.1 depicts a schematic representation of the proposed strategy in order to
simultaneously target both aspects: (a) the BCR-ABL pathway; and (b) the SCF-mediated innate
resistance.
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Figure 3.1: A Suitable Combinatorial Approach to Target Both the Origin of CML and
Innate Resistance. A proposed strategy to block the SCF-mediated innate resistance, in order to
efficiently treat CML involving: (1) targeted drug (e.g., nilotinib) to inhibit the BCR-ABL aspect;
(2) pathway receptor inhibitors (e.g., sAB co-agents) to block the innate resistance mediated by
dimerization of SCF on the receptor c-Kit.
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3.3 Objectives
In order to validate the hypothesis posed above, the following two broad objectives are devel-
oped:
• Objective 1: Propose a combinatorial approach to derive candidate treatments, that simul-
taneously target BCR-ABL and block the SCF-mediated innate resistance, respectively con-
sisting of: (a) targeted drug (e.g., nilotinib); and (b) and pathway receptor inhibitors (e.g.,
c-Kit antibodies).
• Objective 2: Assess the treatment performance of the proposed candidate combinations, to
achieve high potency and specificity, using a set of in vitro tests on suitable CML cell lines.
Overall, these broad objectives aim to deliver combinatorial treatment solutions that have the po-
tential to block the SCF-mediated innate resistance.
3.4 Methodology Overview
To achieve the stated objectives, the corresponding methodology and supporting experiments
will be designed as follows:
• The proposed combinatorial strategy: corresponding to Objective 1, this first stage of the
methodology endeavors to generate treatment candidates with desirable properties.
– Combinatorial approach: as discussed in the above Sec. 3.1, a single-drug solution is
inefficient to both treat the origin of CML and block the SCF-mediated innate resis-
tance. Therefore, a combination of appropriately designed agents will be considered to
target both aspects.
– sABs: to generate effective combinations, the design process should provide agents
exhibiting complementary properties, with multiple possibilities of these agents for
consideration. In this case, to complement the main drug, multiple co-agent candidates
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with the ability to block innate resistance need to be generated. Given these require-
ments, sAB technology is a suitable solution since it is able to:
* exploit given structural knowledge on c-Kit susceptibility, e.g., specific epitopes,
in generating candidates;
* as a versatile design process, synthetically provide a large pool of candidates with
the required complementary properties.
• Assessment of proposed strategy: corresponding to Objective 2, this subsequent stage of
the methodology seeks to quantify the performance of the proposed candidates, in their ca-
pacity to effectively and efficiently treat CML and its innate resistance.
– In particular, three aspects will be considered to assess cell behaviors: cell binding, cell
death, and progenitor inhibition.
– Logistically, as shown in Figure 3.2, the following six in vitro tests will be experi-
mentally conducted to sequentially screen the candidates and derive suitable solutions:
(a) kinetic test; (b) cell binding test; (c) specific binding test; (d) cell viability assay;
(e) apoptosis assay; (f) colony forming cell assay.
In terms of organization, Chapter 4 describes materials, equipment, and protocols utilized for
all experiments in order to support the proposed strategy in Chapter 5. Then, Chapter 6 describes
the assessment methods, and reports corresponding findings.
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Figure 3.2: Schematic Overview of the Assessment Methods. In order to investigate cell be-
haviors, the assessment cycle begins with an initial screening test based on sAB affinity. Once the
affinity requirement has been met, cell binding and specificity assay are performed. These first two
test stages establish the minimum qualification requirements, focusing only on the sAB candidates.
Last but not least, with the addition of BCR-ABL drug, further tests on cell viability, apoptosis,
and colony formation can be conducted.
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4. Experimental Materials and Methods
In order to propose a suitable treatment strategy (to be developed in Chapter 5), various ma-
terials and methods will be needed. The goal of this chapter is to describe these supporting com-
ponents. In particular, to effectively target the c-Kit pathway responsible for the SCF-mediated
innate resistance, materials and protocols germane to designing and producing c-Kit sABs (i.e.,
Fab generation, affinity maturation, IgG antibody expression, and optimization) are described in
Section 4.2.
In addition, to assess the proposed treatment strategy (subsequently presented in Chapter 6),
a number of tissue culture assays will be performed to test binding criteria of sABs and investi-
gate cell behaviors under a combinatorial treatment. These materials, protocols, and data analytic
software applications are described in the following Sections 4.1, 4.3, and 4.4 to complement
Chapter 6, where the rationale of each test and resulting data will be discussed and analyzed with
respect to the experimental performance.
4.1 Materials
In the context of Chapter 6, materials such as chemical reagents, experimental equipment, and
various cell lines and tissue culture conditions will be necessary to conduct all preparation steps
and tissue culture assays in order to obtain meaningful data. This section describes these relevant
materials.
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4.1.1 Chemical Reagents
The experimental reagents used to prepare and conduct all tests are listed in Table 4.1 with
their corresponding supplier names. For instance, as described in Section 4.2.1, to perform kinetic
test for each sAB with the goal of quantifying antibody-protein binding interactions, the reagents
used in preparation and setup steps before operating the forteBio Octet Red 384 system include:
• protein A (biosensor package);
• regeneration buffer;
• reconstituted c-Kit (Recombinant Human CD 117) reagent;
• phosphate-buffered saline (PBS).
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Experimental Reagent Supplier
Annexin V: FITC Apoptosis Detection Kit I BD Pharmingen
APC Annexin V Reagent BD Pharmingen
Goat F(ab’)2 Anti-Human IgG (H+L)-FITC Beckman Coulter
Goat F(ab’)2 Anti-Human IgG (H+L)-PE Beckman Coulter
Nilotinib (100 mg) BioVision Inc.
PerfectPrep™ EndoFree Maxi Kit Manual Fisher Scientific
Protein A (Biosensor Package) forteBIO
Amine Reactive Second-Generation (AR2G)
(Biosensor Package)
forteBIO
Regeneration Buffer forteBIO
N-hydroxysulfosuccinimide (Sulfo-NHS) forteBIO
Ethanolamine (ETA) Reagent forteBIO
Sodium Acetate Buffer forteBIO
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) forteBIO
293fectin™ Transfection Reagent Invitrogen Life Technologies
Blasticidin S HCl (powder) Invitrogen Life Technologies
Fetal Bovine Serum (FBS) Invitrogen Life Technologies
FreeStyle™ 293 Expression Medium Invitrogen Life Technologies
Opti-MEM® Reduced Serum Medium (powder) Invitrogen Life Technologies
Phosphate-Buffered Saline (PBS) (powder) Invitrogen Life Technologies
Penicillin-Streptomycin Solution (10,000 U/mL) Invitrogen Life Technologies
Roswell Park Memorial Institute (RPMI) 1640 Medium,
phenol red (powder)
Invitrogen Life Technologies
Dulbecco’s Modified Eagle Medium (DMEM),
high glucose, phenol red (powder)
Invitrogen Life Technologies
SYTOX® Blue Dead Cell Stain Invitrogen Life Technologies
Trypan Blue Solution (0.4%) Invitrogen Life Technologies
Trypsin-EDTA (0.05%), phenol red Invitrogen Life Technologies
Zeocin™ Selection Reagent Invitrogen Life Technologies
G418 Sulfate InvivoGen
Recombinant Human CD 117/c-kit, CF (50 μg) R&D Systems
Recombinant Human SCF/c-kit Ligand (10 μg) R&D Systems
Recombinant Mouse SCF/c-kit Ligand (10 μg) R&D Systems
MethoCult™ GF M3434 Methylcellulose
(Mouse Cells)
StemCell Technologies
MethoCult™ H4434 Classic Methylcellulose
(Human Cells)
StemCell Technologies
Table 4.1: List of Reagents and Suppliers
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4.1.2 Experimental Equipment
Table 4.2 lists experimental equipment necessary to perform the corresponding tissue culture
assays. For instance, MACSQuant Analyzer is the flow cytometry system used to conduct the
following experiments: cell binding test, non-specific and specific binding test, and apoptosis
assay.
Experimental Equipment Method
AKTA Prime System sAB Purification and Elution
forteBio Octet Red 384 System sAB Quantification;
Kinetic Test
NanoDrop 2000/2000c Spectrophotometer sAB Concentration Measurement
MACSQuant Analyzer Cell Binding Test;
Non-specific and Specific Binding Test;
Apoptosis Assay
Light Microscope Cell Viability Assay
Inverted Microscope Colony Forming Cell Assay
Table 4.2: List of Experimental Equipment
4.1.3 Cell Lines and Tissue Culture Environments
Table 4.3 lists different cell lines, which are utilized in tissue culture assays, to investigate the
effectiveness and repeatability of proposed combinatorial CML treatments.
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Cell Line Description
CJ Murine blast-crisis CML cell line, obtained from the
Craig Jordan Research Lab, with the BCR-ABL and
Nup98/HoxA9 translocation products, and c-Kit ex-
pression [80].
JURL-MK1 Human blast-crisis CML cell line, obtained from the
DSMZ Bioresource Center in Braunschweig, Ger-
many, with one t(9;22) translocation, b3-a2 BCR-
ABL fusion, and c-Kit expression.
KU-812 Human blast-crisis CML cell line, obtained from the
DSMZ Bioresource Center in Braunschweig, Ger-
many, with two t(9;22) translocations, b3-a2 BCR-
ABL fusion, and c-Kit expression.
HEK 293F A specific mammalian cell line, obtained from Life
Technologies, is originally derived from the human
embryonic kidney cells grown in tissue culture.
Table 4.3: List of Cell Lines
The cells are maintained according to manufacturer’s guidelines as follows.
All CML cell lines are utilized for tissue culture assays and maintained in a humidified incu-
bator containing 5% CO2 at 37º C:
• Murine CML cells – CJ – are cultured in Roswell Park Memorial Institute (RPMI) 1640
medium supplemented with 20% volume per volume (v/v) fetal bovine serum (FBS);
• Human CML cells – JURL-MK1 and KU-812 – are cultured in RPMI 1640 medium supple-
mented with 10% v/v FBS and 1% v/v penicillin-streptomycin solution.
Suspension cells are utilized for co-transfection and maintained in a humidified incubator contain-
ing 8% CO2 at 37º C:
• Human embryonic kidney (HEK) 293F cells are cultured in FreeStyle™ 293 Expression
medium.
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4.2 Protocols for Generation of Anti–c-Kit Synthetic Antibodies (sABs)
The protocols necessary for generating anti–c-Kit sABs are described. Specifically, Sections
4.2.1–4.2.3 sequentially summarize the three main stages involved. These steps demonstrate how
the generated anti–c-Kit sABs should serve as suitable starting points for developing combinatorial
treatment candidates, as elaborated later in Chapter 5.
4.2.1 Production of c-Kit Antigen Binding Fragments (Fabs)
The first stage to generate Fabs is described in the following:
With phage display technology, c-Kit Fabs, designed to specifically target the c-Kit D1–D3
region, are generated from in vitro screening and selection strategy. As presented in Figure 4.1, for
a specific Fab designated as Apo A, the screening and selection strategy starts with:
• Immobilized antigens of the purified human c-Kit ectodomain, supplied by the Schlessinger
Lab (Yale University);
• The phage-displayed Fab library known as “Library F”, designed and constructed by the
Sidhu Lab (University of Toronto), which contains more than 1010 unique members that vary
in the amino acid composition of variable heavy domain (VH) complementarity determining
regions (CDRs) 1–3 and variable light domain (VL) CDR 3.
The generation process of Apo A Fab was performed by the Sidhu Lab.
21
Ampl
ication (in E. coli host)
Binding  Selection
Fab Phage Pool
(Library F)
Immobilized Antigens
(Human c-Kit Ectodomain)
Non-Binding Phage
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Figure 4.1: Schematic Diagram of Stage 1 – Generation of Synthetic c-Kit Fabs. In this case,
a c-Kit Fab designated as Apo A is specifically illustrated, with phage display technology allowing
for in vitro screening and selection strategies to select specific binders, using the Library F and
immobilized antigens of the human c-Kit ectodomain.
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4.2.2 Affinity Maturation
The second stage to produce alternative c-Kit Fabs with a potentially improved binding affinity
is described in the following:
1. As illustrated in Figure 4.2, using a soft randomization process, a new oligonucleotide primer
is created based on the parental nucleotide sequence of Apo A to introduce moderated mu-
tations at random positions in the CDR-H1–H3, L3 segments.
2. With the new primer, Kunkel mutagenesis is performed to construct a secondary mutagenic
phage library (i.e., library Apo A) that comprises several mutants of the nucleotide sequence.
3. This new phage library is used in consecutive rounds of biopanning to select specific c-Kit
Fabs with improved binding properties.
4. Once the biopanning is finished, the nucleotide sequence of new c-Kit phagemids is analyzed
using the next-generation sequencing (NGS).
With the goal of fine-tuning the binding affinity and specificity, new c-Kit Fabs (i.e., Apo A1 Fab
and Apo A2 Fab) are generated from an affinity selection, using the mutagenic phage library and
immobilized antigens of the human c-Kit ectodomain. Table 4.4 illustrates the resulting CDR
sequences of Apo A1 Fab and Apo A2 Fab. This affinity maturation process was performed by
Dr. Patricia Cano during her postdoctoral fellowship in the Geyer and DeCoteau Lab.
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Figure 4.2: Schematic Diagram of Stage 2 – Affinity Maturation Process to Produce Alterna-
tive c-Kit Fabs: 1) A soft randomization process is applied to create a new oligonucleotide primer
with moderated mutations at random positions in the CDR-H1–H3, L3 segments of Apo A; 2)
Using the new primer, Kunkel mutagenesis is utilized to construct a secondary mutagenic phage
library (i.e., library Apo A) for affinity selection; 3) To generate new c-Kit Fabs with improved
binding affinity, biopanning is performed using the new mutagenic phage library to select c-Kit
Fabs with desirable properties; and 4) The nucleotide sequence of new c-Kit phagemids is ana-
lyzed using the next-generation sequencing (NGS).
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Table 4.4: Variant CDR Sequences of the New Affinity-Matured Fabs: Apo A Fab - For the
affinity maturation stage, a soft randomization process is applied to the DNA segments of interest
(marked in blue), to introduce moderated mutations at random positions in the CDR-H1–H3, L3
sequences. The corresponding amino acid sequences of the CDR-H1–3, L3 are shown in the next
row; Apo A1 Fab - The new amino acid sequence has several substitutions in the CDR-H1–2,
L3 segments from a successful affinity maturation process; Apo A2 Fab - The new amino acid
sequence has several substitutions in the CDR-H1–3 segments.
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As a result, when compared to the original amino acid sequence of Apo A Fab, the new se-
quence of the Apo A1 Fab has substitutions in the following CDR segments:
1. Valine (V) and arginine (A) for leucine (L) and serine (S), respectively in the amino acid
sequence of CDR-H1;
2. Threonine (T), proline (P), and arginine (A), respectively for serine (S) on locations 1, 4, 8
in CDR-H2;
3. Phenylalanine (F) and aspartic acid (D) for tyrosine (Y) and glycine (G), respectively in
CDR-L3.
Similarly, for the Apo A2 Fab, the new sequence has the following substitutions:
1. Histidine (H), arginine (A), and isoleucine (I) for tyrosine (Y), serine (S), and methion-
ine (M), respectively in CDR-H1;
2. Phenylalanine (F) for tyrosine (Y) in the CDR-H2;
3. Glycine (G) for arginine (A) in the CDR-H3.
4.2.3 Conversion of c-Kit Fabs Into Complete IgG Antibodies
The third stage to convert the c-Kit Fabs into complete sABs consists of the following steps:
1. VH and VL domains are isolated from the Fab phagemid and amplified by polymerase chain
reaction (PCR).
2. DNA encoding VH and VL domains are cloned into the recombinant pFUSE-CHIg and
pFUSE2-CLIg plasmids.
3. The PerfectPrepTM Endofree Maxi Kit facilitates purifying and extracting the recombinant
pFUSE-CHIg and pFUSE2-CLIg plasmids in an advanced transfection-grade condition.
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4. As illustrated in Figure 4.3, using the purified pFUSE-CHIg and pFUSE2-CLIg plasmids,
a transient-plasmid-DNA transfection is performed in accordance with the manufacturer’s
instructions, in order to produce the candidate human IgG sABs. The materials for this step
include 293fectinMT transfection reagent, and the human embryonic kidney (HEK) 293F
cells which should be cultured in the FreeStyleTM 293 Expression medium containing Glu-
taMAX™ supplement for an adequate incubation duration, i.e., 5 days.
5. After incubation, the sABs are purified and extracted from the supernatant, using the A¨KTA-
prime system with the IgG purification and IgG elution buffers.
6. Last, using the forteBio Octet Red 384 system with protein A biosensors, quantification is
performed to measure the antibody concentration for each sAB, in order to select the can-
didates with antibody concentration sufficiently high, i.e., possessing promising properties,
for subsequent assays. In addition, to double check the result accuracy and consistency, the
NanoDrop 2000/2000c Spectrophotometer Version 1.0 software is also used to provide an
independent set of measurements for cross-comparison.
It can be seen that the experiments in this third stage are relevant for validating additional
performance properties. In other words, they serve as criteria for further short-listing of candidates
sABs with desirable properties.
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Figure 4.3: Schematic Diagram of Stage 3 – Converting the c-Kit Fabs Into Complete Syn-
thetic Antibodies. First, VH and VL domains are isolated from the Fab phagemid, amplified by
the PCR, and cloned into the recombinant pFUSE-CHIg and pFUSE2-CLIg expression plasmids.
Through an antibody expression system, using the purified pFUSE-CHIg and pFUSE2-CLIg plas-
mids and a 293fectin reagent, a transient plasmid DNA transfection is applied with the mammalian
cells (e.g., HEK 293F) in order to produce the human IgG sABs.
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4.3 Protocols for Tissue Culture Assays
Various tissue culture assays will be performed to assess the proposed strategy, as presented
later in Chapter 6. This section describes the experimental protocols for these assays.
4.3.1 Kinetic Test
To screen binding tightness and obtain affinity measurements including association constant
(ka), dissociation constant (kd), and equilibrium dissociation constant (KD), kinetic test is per-
formed using the forteBio Octet Red 384 system with bio-layer interferometry (BLI) biosensors,
which uses an optical technique to quantify and analyze biomolecular interactions between sABs
and c-Kit.
The kinetic experimental setup is described and illustrated in Figures 4.4, 4.5, and 4.6 respec-
tively for Apo A IgG, Apo A1 IgG, and Apo A2 IgG.
For each sAB, a microplate is used to prepare the test samples, with 50 μL per each well. The
specific configurations are as follows for the three candidate sABs.
• Apo A IgG with a titration series of 50, 100, 200 and 400 nM of c-Kit concentrations diluted
with phosphate-buffered saline (PBS), using protein A biosensors;
• Apo A1 IgG with a titration series of 25, 50, 100, and 200 nM of c-Kit concentrations diluted
with PBS, using protein A biosensors;
• Apo A2 IgG with a titration series of 50, 100, 200, and 400 nM of c-Kit concentrations di-
luted with sodium acetate buffer at pH 4, using Amine reactive second-generationo (AR2G)
biosensors.
Then, the prepared microplates are individually loaded on the Octet system for kinetic analysis.
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Figure 4.4: The Kinetic Experimental Setup for Apo A IgG Using Protein A Biosensors.
The microplate was prepared with 50 μL of sample per each well (purple) in the respective test
conditions: 1) phosphate-buffered saline (PBS); 2) regeneration buffer; 3) PBS; 4) Apo A IgG
with a concentration of 10 μg/mL diluted with PBS; 5) PBS; 6) a titration series of 400, 200, 100,
and 50 nanomolar (nM) of c-Kit concentrations diluted with PBS; and 7) PBS.
30
1 2 3 4 5 6 7
PBS 
Regeneration
Buer PBS
Apo A1 IgG
(10 μg/mL) PBS
c-Kit
(nM) PBS
200
100
50
25
Protein A Biosensors
Figure 4.5: The Kinetic Experimental Setup for Apo A1 IgG Using Protein A Biosensors.
The microplate was prepared with 50 μL of sample per each well (purple) in the respective test
conditions: 1) phosphate-buffered saline (PBS); 2) regeneration buffer; 3) PBS; 4) Apo A1 IgG
with a concentration of 10 μg/mL diluted with PBS; 5) PBS; 6) a titration series of 200, 100, 50,
and 25 nanomolar (nM) of c-Kit concentrations diluted with PBS; and 7) PBS.
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Figure 4.6: The Kinetic Experimental Setup for Apo A2 IgG Using Amine Reactive Second-
Generation (AR2G) Biosensors. The microplate was prepared with 50 μL of sample per
each well (purple) in the respective test conditions: 1) phosphate-buffered saline (PBS); 2)
regeneration buffer; 3) PBS; 4) 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-
hydroxysulfosuccinimide (sulfo-NHS); 5) Apo A2 IgG with a concentration of 50 μg/mL diluted
with sodium acetate buffer; 6) ethanolamine (ETA); 7) PBS; 8) a titration series of 400, 200, 100,
and 50 nanomolar (nM) of c-Kit concentrations diluted with sodium acetate buffer; and 9) PBS.
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4.3.2 Cell Binding Test
This test allows for assessing the quantity of sABs binding to the cell surface on various CML
cells. The experimental procedure involves immunofluorescence staining and flow cytometry to
optically estimate the level of c-Kit fluorescence.
1. Cells are initially prepared with approximately 300, 000 cells per flow tube, for a set of 3
tubes:
(a) cells;
(b) cells + secondary antibody;
(c) cells + primary antibody (i.e., anti–c-Kit sAB) + secondary antibody.
2. Next, immunofluorescence staining is performed in accordance with the manufacturer’s in-
structions.
3. Then, the prepared test samples are loaded on the flow cytometry system for cell binding
analysis.
It should be noted that, the antibody staining step facilitates the estimation of the cell population
of interest using a secondary antibody conjugated to a fluorochrome, e.g., phycoerythrin (PE) for
murine CML cells or fluorescein isothiocyanate (FITC) for human CML cells. This fact, along
with its rationale, will be further elaborated and utilized later in Section 6.2.
4.3.3 Specific Binding (SB) and Non-Specific Binding (NSB) Tests
For specific binding and non-specific binding tests, the human embryonic kidney (HEK) 293F
cells are utilized to investigate the different binding activities occurring on different cell surface
types: surface with c-Kit molecules (i.e., specific case of interest) versus surface without c-Kit, but
with other surface proteins. The protocol is as follows:
1. To control the presence of c-Kit domain on the cell membrane, a polyethylenimine (PEI)
transfection with c-Kit plasmid DNA is performed in accordance with the manufacturer’s
instructions.
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2. Once transfection is finished, the cell preparation procedure is similar to that in the cell
binding test described above in Section 4.3.2.
3. With the prepared cell samples, the SB and NSB tests proceed as follows:
(a) For SB, the HEK 293F cell line (transfected with c-Kit plasmid DNA) is stained with
primary antibody (i.e., anti–c-Kit sAB) and secondary antibody (conjugated to FITC);
(b) For NSB, the HEK 293F cell line is also stained with both primary and secondary
antibodies.
4. Immunofluorescence staining is performed, also following the same procedure as that de-
scribed above in Section 4.3.2.
5. Then, the prepared test samples are loaded on the flow cytometry system for SB and NSB
analysis.
4.3.4 Cell Viability Assay
To investigate cell behaviors in response to a combinatorial effect on various CML cell lines,
cell viability assay is performed to estimate cell number, using a trypan blue dye to differentiate
viable and non-viable cells.
The protocol for this assay is as follows.
1. First, all CML lines are prepared in triplicate with a cell concentration of 0.5×106 cells/mL,
cultured as described previously in Section 4.1.3, and treated with the combinatorial treat-
ment consisting of c-Kit antibody and nilotinib, applied with stem cell factor (SCF).
2. The following test scenarios are considered:
• [1] - Cells (untreated)
• [2] - Cells + stem cell factor (SCF)
• [3] - Cells + nilotinib (Nil)
• [4] - Cells + SCF + Nil
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• [5] - Cells + antibody (Ab)
• [6] - Cells + Ab + SCF
• [7] - Cells + Ab + Nil
• [8] - Cells + Ab + SCF + Nil
3. The corresponding nilotinib, sAB (including Apo A, Apo A1, and Apo A2 IgG’s), and SCF
concentrations are configured according to Table 4.5.
4. After 40–48 hours of incubation, a culture sample of 10 μLs is then diluted with 10 μLs of
0.4% Trypan Blue dye, and cell counting (i.e., cell density and cell viability in percentage)
is determined using a hemocytometer under a light microscope.
CML Cell Line IC50 Nilotinib 
(nM) 
sABs
[Apo A, Apo A1, and Apo A2 IgG's] 
(µg/mL)
SCF 
(ng/mL)
CJ 50 3 200
KU-­‐812 10 3 200
JURL-­‐MK1 30 3 200
Experimental	  Setup	  for	  Nilotinib,	  sABs,	  and	  SCF
Table 4.5: Experimental Setup for CML Cell Lines. The table lists half maximal inhibitory
concentration (IC50) nilotinib, sAB, and SCF concentrations for all three CML cell lines.
4.3.5 Apoptosis Assay
To identify and measure the apoptotic effect on CML cells, apoptosis assay needs to be per-
formed in order to confirm whether a majority of the cell deaths is caused by a combinatorial
treatment versus a single drug alone.
1. The initial preparation steps of this experimental setup are similar to those in the cell viability
assay.
2. After 40–48 hours of incubation, Annexin V staining is performed in accordance with the
manufacturer’s instructions.
3. Then, the prepared test samples are loaded on the flow cytometry system for apoptosis anal-
ysis.
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4.3.6 Colony Forming Cells (CFC) Assay
To investigate the progenitor ability of CML cells after a combinatorial treatment, CFC assay
needs to be performed to ensure that c-Kit sAB could restore nilotinib effect.
1. The initial preparation steps are similar to those in the cell viability assay.
2. After 40–48 hours of incubation, CFC assay is set up using MethoCult™ methylcellulose-
based medium in accordance with the manufacturer’s instructions. Cells are plated in tripli-
cate at a density of 100–300 cells per 150 μL methylcellulose reagent.
3. Colony formation is quantified under an inverted microscope after 7–14 days of incubation
in a humidified atmosphere.
4.4 Statistical Analyses and Data Presentation
All data analyses including statistical tests are to be performed using IBM SPSS Statistics
Version 20 software for subsequent interpretation and visual presentation. P-values for cell viabil-
ity, apoptosis, and colony formation assay data are calculated using one-tailed Student’s t-test to
compare a combinatorial treatment versus one drug solution. FlowJo Version 8.8.7 is utilized to:
1) generate histogram graphs for cell binding and specific binding tests;
2) process analytical data for apoptosis assay.
Furthermore, all figures, illustrations, and tables are produced using Adobe® Illustrator CC 2014
and Microsoft® Excel 2011.
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5. Proposed Strategy: A Combinatorial Treatment
Using Nilotinib and Anti–c-Kit Synthetic Antibodies
In this chapter, a strategy is provided to potentially reduce the SCF-mediated innate resis-
tance. Here the rationale for designing a suitable combinatorial strategy to improve CML therapy
is presented. More specifically, a targeted therapy approach is possible due to the biochemical
knowledge of the c-Kit pathway, which is responsible in part for innate resistance.
5.1 c-Kit Pathway Revisited for Targeted CML Treatment
The receptor c-Kit (also known as CD117), activated by its ligand SCF, is a member of type III
receptor tyrosine kinase family. It was first identified and characterized in 1987 as the cellular
homologue, encoded by the viral oncogene v-kit, of Hardy-Zuckerman IV feline sarcoma virus
[81, 82].
As previously described in Chapter 2, the SCF/c-Kit pathway is intimately implicated in the
innate resistance mechanism [76, 83]. Even in normal cells, this pathway plays a pivotal role
in maintaining and stimulating diverse biological functions in hematopoiesis, which in mutated
cells are conducive to supporting tumorigenesis, including: cell growth and survival; proliferation
and differentiation, and adhesion and migration [75, 76, 84]. For instance, mutations in the c-Kit
transduction pathway are actively linked to the occurrence of various human cancers, including
gastrointestinal stromal tumors (GISTs) and leukemias [76, 85–87]. In the context of CML, from
a signaling perspective, the c-Kit pathway is responsible for stimulating innate resistance, and this
mechanism is in turn mediated by SCF, one of the crucial hematopoietic cytokines [25,58,77,88].
Stromal SCFs are released by the bone marrow (BM) endosteal niche, where the population of
quiescent LSCs reside and receive protection from these growth factors, in order to activate tyrosine
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kinase inhibitor (TKI) innate resistance [89–91].
Clearly, to reduce innate nilotinib resistance, it is vital to block the c-Kit pathway. In this thesis,
the receptor c-Kit will be targeted to inhibit SCF-mediated signal transduction initialization. To
this end, identifying the structural susceptibility of c-Kit is relevant. The receptor c-Kit is a
type I transmembrane glycoprotein composed of 976 amino acids, with a relative molecular mass
of 145 kDa [77, 92]. The extra-cellular fragment consists of five immunoglobulin-like domains
(D1–D5), which are categorized into two separate functional units: (1) D1–D2–D3 domains are
the essential binding sites of SCF; and (2) D4–D5 domains are the region for homodimerization
of the two receptor c-Kit monomers. The ligand SCF homodimer binds to domains (D1–D2–
D3) of the receptor c-Kit, which results in homodimerization in order to activate the intrinsic
tyrosine kinase activity and drive downstream signal transduction pathways [25, 77, 92–94]. Since
successful interaction between the receptor c-Kit and its ligand SCF is important for activating the
pathway, disrupting this initial interaction is a judicious strategy to disable this pathway, which
can be achieved by targeting the epitopes involved. The integration sites D1–D2–D3 are therefore
precisely the epitopes sought for targeted treatment, since these epitopes are implicated in the
activation of the c-Kit/SCF pathway. Therefore, blocking this SCF signaling should reduce the
protection mechanisms of the LSCs by targeting the binding sites of a SCF homodimer on the
receptor c-Kit with some inhibiting co-agents. The described c-Kit structure and its ligand SCF,
with specific sites as potential targets to block the downstream activation of many intracellular
pathways for therapeutic strategies, are illustrated in Figures 5.1 and 5.2.
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Figure 5.1: Schematic Diagram of c-Kit Structure with Its Ligand SCF. The extra-cellular
fragment consists of five immunoglobulin-like domains (D1–D5). In particular, D1–D2–D3 do-
mains are the essential binding locations for SCF (red), whereas D4–D5 domains are the region
for homodimerization of the receptor c-Kit. The intra-cellular portion contains the tyrosine kinase
domain (blue).
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Figure 5.2: Schematic Diagram of an Activated c-Kit Molecule. Once the ligand SCF ho-
modimer binds to specific domains (D1–D3) on the receptor, the SCF/c-Kit complex results in
homodimerization to activate the intrinsic tyrosine kinase activity, thus driving downstream signal
transduction pathways.
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5.2 sAB Technology: A Versatile Platform for Targeted and Combinatorial
Treatment
The previous section highlights the necessity of targeted treatment to specifically target D1–
D2–D3 domains, which are intimately involved in the pathway activation, and thus represent vul-
nerable sites on the c-Kit molecule [77,92]. Moreover, as a one-drug solution can typically achieve
only limited objectives, a combination of treatments is desired to simultaneously inhibit the BCR-
ABL problem and block the innate resistance. In other words, a suitable solution should involve
a treatment platform that can be flexibly configured to fulfill two perspectives: (1) incorporate
specific structural information in design; (2) amenable to development of combinatorial therapy.
For precisely these reasons, the emerging sAB technology represents a versatile and compelling
solution to be considered. In particular, combinatorial treatments based on sABs have the potential
to achieve high affinity and strong specificity to the selective targets [95].
Antibodies have emerged as a potent molecularly-targeted therapy for human cancer, espe-
cially when combined with other chemotherapy drugs [96]. The combinatorial advantage is also
realized by converting two antibodies into a single bi-specific antibody, to increase the effective
concentration of antigen binding sites and potency [97]. Compared to small-molecule therapeu-
tics, the virtues of antibodies include the ability to simultaneously inhibit the activity of their
target, and also stimulate the immune response to induce cellular cytotoxicity. This characteristic
is strategically important in targeting LSCs, since inhibition of a specific signaling pathway may
be compensated by bone marrow cytokine stimulation of alternative pathways. The antibody ther-
apeutic approach is further facilitated and enhanced by the phage display methodology, in which
sABs can be effectively generated for targeting specific c-Kit domains.
With the state-of-the-art phage display technology, it is possible to screen antigen binding
fragment (Fab) libraries, thus isolating individual Fabs that bind specific targets. Furthermore,
recombinant DNA techniques make it possible to generate fully synthetic libraries of Fabs, with
diverse and customizable properties [98–101]. This synthetic flexibility is a major advantage, since
antibodies with unique and specific characteristics can be generated, which would be otherwise
unattainable if antibodies are limited to the natural repertoires derived from immune cells or present
within hybridoma libraries [30, 102, 103]. In fact, since it is known that the SCF/c-Kit signaling
41
is required for hematopoietic cell development [83, 94], Fabs can be generated to target multiple
signaling sites on the c-Kit ectodomain (i.e., D1–D3 as explained previously).
The illustrations of sABs targeting the D1–D3 domains on the c-Kit receptor are shown in
Figures 5.3 and 5.4. Furthermore, the resulting combinatorial treatment strategy, simultaneously
targeting the c-Kit structure (with sABs) and BCR-ABL (with nilotinib), is as previously shown
in Figure 3.1 from Chapter 3. In this manner, the generated antibodies can inhibit the SCF/c-Kit
pathway in order to restore nilotinib activity for treatments against CML, with high affinity and
specificity. These properties will be validated in the following Chapter 6, describing a comprehen-
sive set of tissue culture assays.
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Figure 5.3: An Overview of How the SCF/c-Kit Pathway Should be Inhibited. Exploiting
advances in the antibody phage display technology, sABs (purple) are generated with unique and
specific characteristics (e.g., high affinity and high specificity) to target the essential binding sites
of SCF on the receptor for pathway activation.
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Figure 5.4: An Overview of Synthetic Antibodies Specifically Targeting D1–D2–D3 Domains
on the Receptor c-Kit. To effectively inhibit the SCF/c-Kit pathway, sABs (purple) are utilized to
specifically target D1–D2–D3 domains (SCF binding sites) on the receptor, thus causing a homod-
imerization of D4–D5 domains in order to deactivate downstream signal transduction pathways.
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5.3 Overview of Anti–c-Kit sAB Generation
In the previous section, a combinatorial methodology involving two agents has been described.
Clearly, to improve the likelihood of successfully deriving an effective combination, the starting
points or input candidates need to possess promising properties. In this thesis, the drug agent is
fixed to be nilotinib, while the promising sAB co-agent will be selected from a pool of c-Kit Fabs
generated using the phage display technology. The goal is to produce sABs with the capacity to
efficiently bind to specific domains on the c-Kit molecule, thus potentially inhibiting the SCF-
mediated innate resistance pathway for a synergistic combinatorial treatment.
In Section 4.2, the protocols necessary to generate such sABs have been described in detail,
and illustrated in Figures 4.1, 4.2, and 4.3. To summarize the generation process depicted in Figure
5.5, the three stages are pursued using the phage display technology [29, 30, 104–106]:
• First stage – generation of c-Kit Fabs specifically targeted to the c-Kit D1–D3 region from
in vitro screening and selection strategies;
• Second stage – affinity maturation to produce alternative c-Kit Fabs with increased binding
affinity for greater sensitivity in assays;
• Third stage – conversion of high affinity c-Kit Fabs into complete sABs, of the Immunoglob-
ulin G (IgG) isotype, to perform subsequent tests on CML cells.
It should be noted that there are three other c-Kit Fabs generated: Apo B Fab, and two vari-
ants created from affinity maturation, i.e., Apo B1 Fab and Apo B2 Fab. However, the specific
sequences with various substitutions in the CDR segments are not shown explicitly in this thesis,
since these Fabs were found to fail the third stage, i.e., conversion of c-Kit Fabs into complete IgG
antibodies.
In summary, of the six candidates anti–c-Kit sABs, only three were found to be the potential
antibody co-agents. In other words, the subsequent assays will be pursued with Apo A, Apo A1
and Apo A2 sABs only, as described and conducted in Chapter 6.
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Figure 5.5: Three Stages Utilized to Generate and Express c-Kit Fabs into Human IgG sABs.
1) Using the phage display technology, Apo A Fab is generated to specifically target the c-Kit
D1–D3 region; 2) With the goal of fine-tuning the binding affinity and specificity, alternative Fabs
(i.e., Apo A1 Fab and Apo A2 Fab) are produced from an affinity maturation; and 3) c-Kit Fabs
are expressed into human IgG sABs to perform tissue culture assays on CML cells.
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6. Results and Data Analyses: Assessing the Ability of
Anti–c-Kit sAB to Block SCF-Mediated Innate
Resistance
In this chapter, the experimental results obtained from a strategically designed set of tests are
first reported, followed by suitable data analysis in order to reveal the effectiveness of the proposed
combinatorial approach. In particular, the ability of sABs to enhance combinatorial treatment
with nilotinib for CML will be tested in vitro using kinetic, cell binding, viability, apoptosis, and
colony forming cell assays. It will be seen that all tests support the promising potential of sABs to
block the SCF pathway in order to mitigate LSCs, thus enhancing the effectiveness of nilotinib in
addressing innate resistance.
Unless otherwise specified, all data analyses including statistical tests were performed in SPSS
version 20 by IBM, with suitable graphs generated accordingly for subsequent interpretation.
6.1 Kinetic Test: Screening for Suitable Co-Agents Based on sAB Affinity
Since binding needs to at least occur before other types of interaction between sABs and cells
can even be meaningfully considered, ensuring that binding tightness has in fact been achieved
should be the first condition to be validated. Once this binding criterion has been successfully
met, other follow-up tests will be investigated. Therefore, the first test applied was the kinetic test,
with the objective of measuring the affinity of an antibody-protein interaction, which quantifies the
binding tightness of an antibody to its target. This kinetic test was performed using the forteBio
Octet system, which includes an Octet Red 384 16-channel instrument, bio-layer interferometry
(BLI) biosensors, reagents and assay kit to perform real-time quantification of IgG concentrations
and high-sensitivity kinetic analysis of antibody-protein binding interactions in an accelerated and
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efficient manner. The Octet system incorporates a Dip and Read BLI biosensor technology that
emits incident white light down the biosensor and collects the reflected light from two surfaces: 1)
a layer of immobilized protein on the biosensor tip, and 2) an internal reference layer. This system
uses an optical technique to measure and analyze biomolecular interactions between immobilized
antibodies (i.e., anti–c-Kit sABs) and protein molecules (i.e., c-Kit) in real-time. A layer of any
molecules attached to the biosensor tip of an optical layer creates a wave interference pattern,
which is captured by a spectrometer at the detector. Any change in the number of molecules bound
to the tip triggers a spectral shift in the interference pattern and generates a response profile on the
system, thus directly quantifying the change in optical thickness of the coating on the biological
layer [107].
As illustrated in Figure 6.1, in the process of antibody loading, c-Kit sABs are first attached
to the biosensor tip surface, which creates an interference pattern at the detector. Once the c-Kit
molecules in solution bind or associate to immobilized sABs at the tip surface, this antibody-
protein interaction causes a spectral shift in the interference pattern that directly quantifies an
increase in optical thickness at the biosensor layer. In contrast, when the c-Kit molecules dissociate
from immobilized sABs, this corresponding event causes another wavelength shift to quantify a
decrease in optical thickness at the biosensor tip. Overall, the association and dissociation of
interacting sABs bound to the c-Kit are assayed by the Octet system, thus quantifying the binding
activity and producing the association and dissociation curves on the kinetic graph [107].
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Figure 6.1: Schematic Diagram for Association and Dissociation of Anti–c-Kit sABs, as De-
livered by the Octet System: 1) The Octet system uses buffer for the baseline step; 2) In the
antibody loading step, sABs are first bound to the biosensor tip surface; 3) Next, the system uses
buffer for another baseline step; 4) For association, the c-Kit molecules in solution bind to immo-
bilized sABs at the tip surface to cause an antibody-protein interaction; and 5) For dissociation,
the system uses buffer to separate the c-Kit molecules from immobilized sABs. The Octet system
quantifies the association and dissociation of sABs bound to the c-Kit, in order to produce the
association and dissociation curves on the kinetic graph.
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For kinetic measurement, the forteBio Octet Red 384 system — with protein A and amine re-
active second-generation (AR2G) biosensors — was utilized to quantitatively determine the equi-
librium dissociation constant (KD ). To enable useful visual characterization, the following kinetic
parameters will be investigated: KD and KD,error, which respectively quantify: (i) the affinity of
the antibody for its target; and (ii) accuracy and reliability of the KD measurement.
KD,error is reported by the Octet instrumentation system, whereas KD is calculated as follows
[108, 109]:
KD =
kd
ka
[M] (6.1)
where
1. ka, in units of 1 over molar over second [1/(Ms)]: an association constant characterizing
how quickly an antibody binds to its specific target;
2. kd, in units of 1 over second [1/s]: a dissociation constant characterizing how quickly an
antibody separates off from its specific target.
6.1.1 Kinetic Data for the sABs
For this test, the kinetic experimental setup for each sAB was as follows:
• Apo A IgG with a titration series of 50, 100, 200 and 400 nM of c-Kit concentrations, using
protein A biosensors;
• Apo A1 IgG with a titration series of 25, 50, 100, and 200 nM of c-Kit concentrations, using
protein A biosensors;
• Apo A2 IgG with a titration series of 50, 100, 200, and 400 nM of c-Kit concentrations,
using AR2G biosensors.
The corresponding protocol for this kinetic test is as described previously in Section 4.3.1.
Then, the obtained kinetic plots for Apo A IgG, Apo A1 IgG, and Apo A2 IgG are respectively
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shown in Figures 6.2, 6.3, and 6.4, and kinetic tables in Tables 6.1, 6.2, and 6.3. These data sets
were analyzed with forteBio Octet global curve fitting to produce the associated KD and KD error
values, which are also reported in the respective tables.
The following general observations can be made (see also Figure 6.1 for guidelines on data
interpretation):
• Figure 6.2 and Table 6.1 illustrate a full kinetic characterization of the interaction between
Apo A IgG and each c-Kit concentration from a titration series, as described above in the
experimental setup. Using this titration series, the average KD calculated for Apo A IgG is
28.55 nM and the average KD error is 0.82 nM.
• Similarly, from Figure 6.3 and Table 6.2, the average KD for Apo A1 IgG is 2.90 nM and
the average KD error is 0.06 nM.
• And likewise, from Figure 6.4 and Table 6.3, the average KD for Apo A2 IgG is 5.68 nM
and the average KD error is 0.32 nM.
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Figure 6.2: Kinetic Characterization of the Binding Interaction Between Apo A IgG and c-
Kit: The kinetic graph illustrates association and dissociation curves for Apo A IgG and different
c-Kit concentrations, using proteinA biosensors. The red curves represent the statistical fitting of
curves; whereas the green, turquoise, brown, and blue curves represent experimental data of the
binding interaction between Apo A IgG and a titration series of 50, 100, 200, and 400 nM of c-Kit
concentrations, respectively.
c-Kit Concentration (nM) KD (nM) KD Error (nM)
50 33.40 2.050
100 19.90 0.291
200 25.10 0.314
400 35.80 0.606
Mean%KD%(nM) 28.55
Mean%KD%Error%(nM) 0.815
Kinetic%Characterization%of%the%c8Kit:Apo%A%IgG%Interaction%%%%
(Using3Protein3A3Biosensors)
Table 6.1: KD and KD error for Apo A IgG. The table lists KD, KD error, average KD , and
average KD error, which are calculated based on four different c-Kit concentrations.
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Figure 6.3: Kinetic Characterization of the Binding Interaction Between Apo A1 IgG and c-
Kit: The kinetic graph illustrates association and dissociation curves for Apo A1 IgG and different
c-Kit concentrations, using proteinA biosensors. The red curves represent the statistical fitting of
curves; whereas the orange, green, turquoise, and brown curves represent experimental data of the
binding interaction between Apo A1 IgG and a titration series of 25, 50, 100, and 200 nM of c-Kit
concentrations, respectively.
c-Kit Concentration (nM) KD (nM) KD Error (nM)
25 2.93 0.1200
50 2.66 0.0355
100 2.64 0.0298
200 3.35 0.0657
Mean%KD%(nM) 2.90
Mean%KD%Error%(nM) 0.0628
Kinetic%Characterization%of%the%c8Kit:Apo%A1%IgG%Interaction%(Using4
Protein4A4Biosensors)
Table 6.2: KD and KD error for Apo A1 IgG. The table lists KD, KD error, average KD , and
average KD error, which are calculated based on four different c-Kit concentrations.
53
Figure 6.4: Kinetic Characterization of the Binding Interaction Between Apo A2 IgG and c-
Kit: The kinetic graph illustrates association and dissociation curves for Apo A2 IgG and different
c-Kit concentrations, using AR2G biosensors. The red curves represent the statistical fitting of
curves; whereas the green, turquoise, brown, and blue curves represent experimental data of the
binding interaction between Apo A2 IgG and a titration series of 50, 100, 200, and 400 nM of c-Kit
concentrations, respectively.
c-Kit Concentration (nM) KD (nM) KD Error (nM)
50 3.10 0.251
100 2.71 0.170
200 7.75 0.340
400 9.14 0.522
Mean%KD%(nM) 5.68
Mean%KD%Error%(nM) 0.321
Kinetic%Characterization%of%the%c:Kit:Apo%A2%IgG%Interaction%(Using2
Amine2Reactive22nd2Generation2Biosensors)
Table 6.3: KD and KD error for Apo A2 IgG. The table lists KD, KD error, average KD , and
average KD error, which are calculated based on four different c-Kit concentrations.
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6.1.2 Data Analysis and Discussion: All Candidate Co-Agents Are Feasible After
Screening
The KD values generated from the obtained graphs and tables quantify the binding affinity due
to each sAB with a titration series of c-Kit target measured against an immobilized antibody. In
other words, high affinity antibodies (i.e., with low KD values) have strong binding to their specific
targets and low affinity antibodies (i.e., with high KD values) have weak binding. Clearly, for
therapeutic cancer applications, we seek to develop high affinity sABs for effective treatment.
According to known literature, most antibodies have KD values in the low micromolar (10-6)
to nanomolar (10-9) range. In particular, high affinity antibodies are usually considered to be in the
low nanomolar range (10-9) [108–112]. With this reference threshold, in the context of the binding
affinity data obtained from the forteBio Octet System, the following corresponding observations
can be made:
• Apo A IgG has a high affinity for its target on the receptor c-Kit, since the obtained KD is in
the low nanomolar range.
• Apo A1 IgG exhibits an even higher affinity for its specific antigen compared to Apo A IgG.
• Apo A2 IgG shows the highest affinity for its target.
Overall, the kinetic test reveals that all three sABs have small KD in the low nanomolar range with
the Apo A2 IgG being the preferred candidate according to this test.
With significantly low KD data, all three sABs exhibit high affinity and sensitivity. These results
indicate that all candidates are feasible and further tests should be pursued for each antibody, in
order to develop the suitable CML treatment solution from multiple test perspectives.
6.2 Cell Binding Test: Assessing the Quantity of sABs Binding to the Cell
Surface of CML Cells
After kinetic test has confirmed tight binding, the next procedure to be performed should be
cell binding test for the sABs. This test measures the number of sABs binding to the cell surface
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on various CML cell lines, in order to assess how many sABs actually achieve tight binding. This
is a significant quantity, to complement the tight binding confirmation provided by the kinetic test,
since it indicates the effectiveness of cell and sAB interactions.
The cell binding test involves immunofluorescence staining and flow cytometry to optically
estimate the level of cell binding. This is achieved by probing with a receptor-specific antibody
indirectly tagged with a fluorophore and measuring the level of c-Kit fluorescence, in order to in-
vestigate the binding events of sABs to c-Kit molecules on various CML cell lines. In this test, as
illustrated in Figure 6.5, CML cells are stained and incubated with: 1) primary antibody (i.e., anti–
c-Kit sAB); and 2) secondary antibody, which is conjugated with a fluorochrome. This labeled
secondary antibody binds to the primary antibody’s fragment crystallizable region (Fc region) to
indirectly detect target antigens. Specifically, a gating procedure is applied for this test, in which
unstained cells represent a negative cell population, stained cells with a fluorochrome-labeled sec-
ondary antibody correspond to a reference cell population of the gating system, and stained cells
with both primary and secondary antibodies represent a positive cell population. In other words,
flow cytometry histograms measure c-Kit antibody fluorescence by assessing a percentage of CML
cells exhibiting binding events between sABs and c-Kit. A histogram of the negative cell popula-
tion shows the background fluorescence in the absence of both primary and secondary antibodies;
whereas a histogram of a reference cell population exhibits the conjugated antibody fluorescence
in the presence of secondary antibody, but devoid of the primary antibody; and a histogram of
the positive cell population measures the c-Kit fluorescence in the presence of primary antibody.
Therefore, given such a gating system, a significant increase or right shift in immunofluorescence
intensity passing the gating system on a reference cell population is a desirable outcome, since a
positive result implies that there are significant binding activities between sAB and receptor surface
proteins on various CML cell lines.
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Figure 6.5: Schematic Diagram for Cell Binding of sABs to c-Kit Molecules on Cell Mem-
brane: Cell binding test involves immunofluorescence staining and flow cytometry to optically
measure the level of c-Kit fluorescence, by probing with primary antibodies (i.e., anti–c-Kit sABs
in purple) indirectly tagged with a fluorophore (green star). This fluorescence measurement allows
estimation of the number of binding events of sABs to c-Kit molecules (gray).
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6.2.1 Data for Cell Binding Test with CML Cell Lines
As described in the procedure in Section 4.3.2, the immunofluorescence staining involves the
following cells:
• unstained cells;
• stained cells, comprising of:
– unconjugated primary antibody (i.e., anti–c-Kit sAB);
– labeled secondary antibody conjugated to a fluorochrome, e.g., fluorescein isothio-
cyanate (FITC) with operational wavelength range of 494–520 nm, or phycoerythrin
(PE), an accessory photosynthetic pigment found in red algae, with operational wave-
length of 496–578 nm.
It should be noted that, in this case, the antibody staining procedure facilitates the estimation of the
cell population of interest using a conjugated fluorochrome-labeled secondary antibody (as such,
the unconjugated primary antibody is not fluorochrome labeled).
For this cell binding test, the experimental setup was as follows:
• murine CML cell line (CJ cells) was stained with primary antibody (i.e., anti–c-Kit sAB)
and secondary antibody (conjugated to PE);
• human CML cell lines (KU-812 cells and JURL-MK1 cells) were stained with primary an-
tibody and secondary antibody (conjugated to FITC).
In the following graphs showing the intensity output, as delivered by the analytical software FlowJo
Version 8.8.7, a right shift in immunofluorescence intensity passing a reference cell population
corresponds to a desirable result. Figures 6.6, 6.7, 6.8 show the binding test results respectively
for CJ, KU-812, and JURL-MK1 cell lines.
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Figure 6.6: Cell Binding Test on CJ Cells for: (a) Anti-human IgG - PE (secondary antibody);
(b) Apo A IgG; (c) Apo A1 IgG; and (d) Apo A2 IgG. A yellow shaded histogram represents a
negative cell population; whereas a red dashed histogram corresponds to a reference cell population
in the presence of conjugated antibody; and a purple solid histogram represents a positive cell
population in the presence of primary antibody.
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Figure 6.7: Cell Binding Test on KU-812 Cells for: (a) Anti-human IgG - FITC (secondary anti-
body); (b) Apo A IgG; (c) Apo A1 IgG; and (d) Apo A2 IgG. A pink shaded histogram represents
a negative cell population; whereas a green dashed histogram corresponds to a reference cell pop-
ulation in the presence of conjugated antibody; and a purple solid histogram represents a positive
cell population in the presence of primary antibody.
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Figure 6.8: Cell Binding Test on JURL-MK1 Cells for: (a) Anti-human IgG - FITC (secondary
antibody); (b) Apo A IgG; (c) Apo A1 IgG; and (d) Apo A2 IgG. A pink shaded histogram rep-
resents a negative cell population; whereas a green dashed histogram corresponds to a reference
cell population in the presence of conjugated antibody; and a purple solid histogram represents a
positive cell population in the presence of primary antibody.
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6.2.2 Data Analysis and Discussion: A Majority of Anti–c-Kit sABs for Each Can-
didate Achieves Tight Binding to the Cell Surface
In all cases, the developed sABs successfully induced a right shift in immunofluorescence
intensity. This implies that the majority of the c-Kit antibodies achieved tight binding for various
CML cell lines, and as such should be good candidates for CML treatment from a cell binding
perspective. Notably, the JURL-MK1 cell line exhibits the best cell binding data, with the highest
shift values, compared to other CML cell lines tested. This means that the developed sABs bound
well to receptor proteins (i.e., c-Kit molecules) on the cell surface of this particular cell line, thus
achieving a strong binding interaction.
6.3 Specific Binding (SB) and Non-Specific Binding (NSB) Tests: Assessing
the sAB Binding Activity, with Respect to the Target c-Kit Domains
While the previous cell binding test reveals insights about the quantity of sABs binding to the
cell surface of various CML cell lines, it is unable to differentiate the different binding activities oc-
curring on different cell surface types: surface with c-Kit molecules (i.e., specific case of interest)
versus surface without c-Kit, but with other molecule types (i.e., non-specific cases not of interest,
including other receptors, transporters, or proteins). This differentiation is important to assess the
effectiveness of the sABs in specifically targeting cKit molecules. Therefore, the next procedure to
be performed is a pair of tests: the non-specific binding (NSB) test, and specific binding (SB) test.
Designed to quantify the binding activities of interest, the SB test involves measuring the number
of binding events for sABs to cells with specific receptors of interest (i.e., c-Kit molecules) on their
surface. By contrast, the NSB test involves measuring the number of binding events for sABs to
cells without specific receptors of interest (i.e., no c-Kit molecules).
It should be noted that, since the underlying flow cytometry technique is not inherently suitable
for distinguishing different binding types, the two tests are conducted separately, while keeping the
same experimental parameters, except for the c-Kit presence in the former SB test, and absence in
the latter NSB test. In other words, the goal of this procedure is to quantify binding events between
sABs and different surface molecular targets presented in two different cell populations, which are
configured with the same measurement settings (e.g., volume, cell concentration, and primary and
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secondary antibody staining, etc.). For a successful treatment, it is clear that more binding activities
should be observed for the sABs in the cell population with c-Kit molecules (i.e., SB case). This
would mean that the specifically designed sABs are in fact behaving as expected: targeting specific
c-Kit domains, resulting in higher binding events when c-Kit molecules are actually present on the
cell surface.
Procedurally, to prepare two different cell populations, the pre-step uses a specific cell line
originally derived from human embryonic kidney (HEK) cells, to facilitate controlling the pres-
ence or absence of c-Kit on the cell surface. In particular, the HEK 293F is a specific cell line
amenable to the use of polyethylenimine (PEI) transfection with c-Kit plasmid DNA for SB test.
This experiment is based on similar cell preparation and immunofluorescence staining as in the
cell binding test, which means that a right shift in immunofluorescence intensity is also a desirable
outcome.
6.3.1 Data for SB and NSB Tests with the HEK 293F Cell Line
As procedurally described in Section 4.3.3, the experimental setup was as follows:
• For SB, the HEK 293F cell line (transfected with c-Kit plasmid DNA) was stained with
primary antibody (i.e., anti–c-Kit sAB) and secondary antibody (conjugated to FITC);
• For NSB, the HEK 293F cell line was also stained both primary and secondary antibodies.
First, for the gating system, Figure 6.9 shows unstained cells and stained cells with secondary
antibodies conjugated to FITC. Then, Figures 6.10, 6.11, and 6.12 show the SB and NSB test
results for the HEK 293F cell line with respectively Apo A, Apo A1, and Apo A2 IgG’s. For NSB
on the HEK 293F cells, the data show no significant right shift in immunofluorescence intensity. By
contrast, for the SB on the HEK 293F cells with c-Kit molecules, the results indicate a significant
right shift as expected. For this test, data were also processed using FlowJo Version 8.8.7 to
generate suitable graphs for subsequent data analysis.
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Figure 6.9: Cell Binding Tests for Secondary Antibody on the HEK 293F cells: (a) Specific
Binding (SB) Case – binding activities on cells with the presence of c-Kit molecules; (b) Non-
Specific binding (NSB) Case – binding activities on cells with the absence of c-Kit molecules. A
peach shaded histogram represents a negative cell population; whereas a green dashed histogram
corresponds to a reference cell population in the presence of conjugated antibody.
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(b) NSB – Cell Surface without c-Kit Molecules
Figure 6.10: Cell Binding Tests for Apo A IgG on the HEK 293F Cells: (a) Specific Binding
(SB) Case – binding activities on cells with the presence of c-Kit molecules; (b) Non-Specific
binding (NSB) Case – binding activities on cells with the absence of c-Kit molecules. A peach
shaded histogram represents a negative cell population; whereas a green dashed histogram corre-
sponds to a reference cell population in the presence of conjugated antibody; and a blue or gray
solid histogram represents a positive cell population in the presence of Apo A IgG.
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(b) NSB – Cell Surface without c-Kit Molecules
Figure 6.11: Cell Binding Tests for Apo A1 IgG on the HEK 293F Cells: (a) Specific Bind-
ing (SB) Case – binding activities on cells with the presence of c-Kit molecules; (b) Non-Specific
binding (NSB) Case – binding activities on cells with the absence of c-Kit molecules. A peach
shaded histogram represents a negative cell population; whereas a green dashed histogram corre-
sponds to a reference cell population in the presence of conjugated antibody; and a blue or gray
solid histogram represents a positive cell population in the presence of Apo A1 IgG.
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(b) NSB – Cell Surface without c-Kit Molecules
Figure 6.12: Cell Binding Tests for Apo A2 IgG on the HEK 293F Cells: (a) Specific Bind-
ing (SB) Case – binding activities on cells with the presence of c-Kit molecules; (b) Non-Specific
binding (NSB) Case – binding activities on cells with the absence of c-Kit molecules. A peach
shaded histogram represents a negative cell population; whereas a green dashed histogram corre-
sponds to a reference cell population in the presence of conjugated antibody; and a blue or gray
solid histogram represents a positive cell population in the presence of Apo A2 IgG.
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6.3.2 Data Analysis and Discussion: The sABs Are Indeed Specifically Bound to
c-Kit Domains
Given the obtained immunofluorescence data, it can be seen that:
• In the SB case, more significant binding activities of sABs and receptor proteins of interest
were measured on the HEK 293F cells in the presence of c-Kit domains;
• In the NSB case, weak binding interactions of sABs and other cell surface proteins were
observed on the HEK 293F cells in the absence of c-Kit domains.
With these NSB and SB tests, the flow system quantifies binding events of sABs to their targets
in two separate cell populations. The key of this procedure is to confirm more significant binding
activities for sABs to their specific targets in the SB case (with c-Kit molecules on cell surface),
compared with those in the NSB case (without c-Kit molecules). As expected, the immunofluores-
cence histograms from the obtained data confirmed that more significant binding of sABs to cells
with c-Kit molecules. And the higher SB activities consistently occurred with all three candidates
of anti–c-Kit sABs. In other words, this result is indeed compatible with the desired requirements
on binding specificity: the presence of c-Kit molecules on the HEK 293F cells should determine,
or be correlated with, the binding activities of the candidate sABs. As such, the NSB test exhibits
fewer binding activities compared to SB test, since by design the former scenario corresponds to
cells devoid of c-Kit molecules. By contrast, in the latter SB test, with HEK 293F cells transfected
with c-Kit plasmid DNA, there are more significant binding activities on the cell surface due to
c-Kit presence. This finding quantitatively demonstrates that the specifically developed sABs were
indeed able to bind c-Kit molecules on cell surface, thus conducive to high affinity and specificity,
which are certainly crucial characteristics of effective and efficient cancer treatment. To this end,
the next set of tests will focus on the treatment effects of the proposed combinations of drug and
sABs.
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6.4 Cell Viability Assay: Investigation of Growth Inhibition Using a Com-
binatorial Treatment
The tests conducted hitherto focus only on the binding criteria of the candidate sABs. There-
fore, an investigation of cell behaviors in response to a combinatorial effect is assessed on various
CML cell lines after the kinetic and cell binding tests. To this end, the next test to be performed is
the cell viability assay, to confirm that a combination of sABs and drug treatments promotes more
significant cell death compared to a single drug treatment alone. This test utilizes microscopic cell
counting technique with trypan blue stain to investigate cell death and cell density. In this case, the
test is applied on various combinations of sABs and drug treatments, for several CML cell lines.
In other words, cell viability is statistically estimated as the number of viable cells divided by the
total number of cells within selected grids of the hemacytometer, under a microscope. Trypan blue
staining facilitates the visualization of cell morphology, thus enhancing the discrimination between
viable and non-viable cells. Specifically, non-viable cells take up the trypan blue dye, whereas vi-
able cells remain unstained due to intact cell membranes. Under a microscope, the staining process
can thus visually separate non-viable cells (blue color) from viable cells (clear).
6.4.1 Data for Cell Viability Assay with CML Cell Lines
For this viability assay, the following scenarios were considered:
• [1] - Cells (untreated)
• [2] - Cells + stem cell factor (SCF)
• [3] - Cells + nilotinib (Nil)
• [4] - Cells + SCF + Nil
• [5] - Cells + antibody (Ab)
• [6] - Cells + Ab + SCF
• [7] - Cells + Ab + Nil
• [8] - Cells + Ab + SCF + Nil
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Each of the above test scenarios was performed in triplicate, with all CML cell lines. The cor-
responding experimental setup is summarized in Table 4.5 (Section 4.3.4) for nilotinib, sAB (in-
cluding Apo A, Apo A1, and Apo A2 IgG’s), and SCF concentrations. Furthermore, cell counting
was determined after 40–48 hours of incubation, in a humidified atmosphere containing 5% CO2
at 37º C.
To facilitate subsequent interpretation and comparison, the graphs were grouped according to
cell line as follows:
• CJ: results shown in Figures 6.13–6.15;
• KU-812: results shown in Figures 6.16–6.18;
• JURL-MK1: results shown in Figures 6.19–6.21.
In each group, the combination consists of nilotinib and one of the sABs (Apo A, Apo A1, or
Apo A2 IgG’s). The effect of SCF is also investigated, i.e., measurements were made both in
the absence and in the presence of SCF conditions. Using one-tailed Student’s t-test, p-values
for cell viability were also evaluated to enable statistical significance assessment, specifically for
comparative pairs of a single drug application versus a combination of treatments, with and without
SCF conditions.
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Figure 6.13: Viability Assay for CJ Cells in a Combination of Apo A IgG and Nilotinib
Treatments. The combinatorial treatment consists of 3 μg/mL Apo A IgG and 50 nM nilotinib
(Nil), applied with 200 ng/mL recombinant mouse stem cell factor (rm SCF). Cells were cultured
in RPMI 1640 medium supplemented with 20% v/v FBS, and maintained in a humidified incubator
containing 5% CO2 at 37º C for 40 hours before the assay. In the graph, black shaded bars represent
the cell viability (%), whereas white shaded bars denote the viable cell number (1 x 106 cells/mL).
P-values for cell viability were calculated in the test pair labeled 3 and 7, and pair 4 and 8 to
compare a combinatorial treatment versus one drug solution. In the treatment annotation table
below the graph, a dash (-) stands for the absence of the corresponding treatment factor. For
example, the first column with 3 dashes corresponds to a null condition, i.e., without an antibody,
SCF, or drug.
71
1 0 0
8 0
6 0
4 0
2 0
0
2,500,000
2,000,000
1,500,000
1,000,000
500,000
0
1              2               3              4               5              6               7               8  
p < 10-3
p < 10-4
Ce
ll 
Vi
ab
ili
ty
 (%
)
Viability Assay for CJ Cells in a Combination of
Apo A1 IgG and Nilotinib Treatments
Viable Cell N
um
ber (1 x 10
6 cells/m
L)
Apo A1 IgG              -                  -                   -                  -            Apo A1     Apo A1     Apo A1      Apo A1
rm SCF                       -               SCF               -                SCF               -               SCF               -                SCF
Nilotinib                    -                  -                Nil              Nil                 -                  -                Nil               Nil
Cell Viability (%)
Viable Cell Number (1 x 106 cells/mL)
Error Bars:  95% CI
Figure 6.14: Viability Assay for CJ Cells in a Combination of Apo A1 IgG and Nilotinib
Treatments. The combinatorial treatment consists of 3 μg/mL Apo A1 IgG and 50 nM nilotinib
(Nil), applied with 200 ng/mL recombinant mouse stem cell factor (rm SCF). Cells were cultured
in RPMI 1640 medium supplemented with 20% v/v FBS, and maintained in a humidified incubator
containing 5% CO2 at 37º C for 40 hours before the assay. In the graph, black shaded bars represent
the cell viability (%), whereas white shaded bars denote the viable cell number (1 x 106 cells/mL).
P-values for cell viability were calculated in the test pair labeled 3 and 7, and pair 4 and 8 to
compare a combinatorial treatment versus one drug solution. In the treatment annotation table
below the graph, a dash (-) stands for the absence of the corresponding treatment factor.
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Figure 6.15: Viability Assay for CJ Cells in a Combination of Apo A2 IgG and Nilotinib
Treatments. The combinatorial treatment consists of 3 μg/mL Apo A2 IgG and 50 nM nilotinib
(Nil), applied with 200 ng/mL recombinant mouse stem cell factor (rm SCF). Cells were cultured
in RPMI 1640 medium supplemented with 20% v/v FBS, and maintained in a humidified incubator
containing 5% CO2 at 37º C for 40 hours before the assay. In the graph, black shaded bars represent
the cell viability (%), whereas white shaded bars denote the viable cell number (1 x 106 cells/mL).
P-values for cell viability were calculated in the test pair labeled 3 and 7, and pair 4 and 8 to
compare a combinatorial treatment versus one drug solution. In the treatment annotation table
below the graph, a dash (-) stands for the absence of the corresponding treatment factor.
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Figure 6.16: Viability Assay for KU-812 Cells in a Combination of Apo A IgG and Nilotinib
Treatments. The combinatorial treatment consists of 3 μg/mL Apo A IgG and 10 nM nilotinib
(Nil), applied with 200 ng/mL recombinant human stem cell factor (rh SCF). Cells were cultured in
RPMI 1640 medium supplemented with 10% v/v FBS and 1% v/v penicillin-streptomycin solution,
and maintained in a humidified incubator containing 5% CO2 at 37º C for 48 hours before the
assay. In the graph, black shaded bars represent the cell viability (%), whereas white shaded bars
denote the viable cell number (1 x 106 cells/mL). P-values for cell viability were calculated in the
test pair labeled 3 and 7, and pair 4 and 8 to compare a combinatorial treatment versus one drug
solution. In the treatment annotation table below the graph, a dash (-) stands for the absence of the
corresponding treatment factor. For example, the first column with 3 dashes corresponds to a null
condition, i.e., without an antibody, SCF, or drug.
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Figure 6.17: Viability Assay for KU-812 Cells in a Combination of Apo A1 IgG and Nilotinib
Treatments. The combinatorial treatment consists of 3 μg/mL Apo A1 IgG and 10 nM nilotinib
(Nil), applied with 200 ng/mL recombinant human stem cell factor (rh SCF). Cells were cultured in
RPMI 1640 medium supplemented with 10% v/v FBS and 1% v/v penicillin-streptomycin solution,
and maintained in a humidified incubator containing 5% CO2 at 37º C for 48 hours before the
assay. In the graph, black shaded bars represent the cell viability (%), whereas white shaded bars
denote the viable cell number (1 x 106 cells/mL). P-values for cell viability were calculated in the
test pair labeled 3 and 7, and pair 4 and 8 to compare a combinatorial treatment versus one drug
solution. In the treatment annotation table below the graph, a dash (-) stands for the absence of the
corresponding treatment factor.
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Figure 6.18: Viability Assay for KU-812 Cells in a Combination of Apo A2 IgG and Nilotinib
Treatments. The combinatorial treatment consists of 3 μg/mL Apo A2 IgG and 10 nM nilotinib
(Nil), applied with 200 ng/mL recombinant human stem cell factor (rh SCF). Cells were cultured in
RPMI 1640 medium supplemented with 10% v/v FBS and 1% v/v penicillin-streptomycin solution,
and maintained in a humidified incubator containing 5% CO2 at 37º C for 48 hours before the
assay. In the graph, black shaded bars represent the cell viability (%), whereas white shaded bars
denote the viable cell number (1 x 106 cells/mL). P-values for cell viability were calculated in the
test pair labeled 3 and 7, and pair 4 and 8 to compare a combinatorial treatment versus one drug
solution. In the treatment annotation table below the graph, a dash (-) stands for the absence of the
corresponding treatment factor.
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Figure 6.19: Viability Assay for JURL-MK1 Cells in a Combination of Apo A IgG and Nilo-
tinib Treatments. The combinatorial treatment consists of 3 μg/mL Apo A IgG and 30 nM nilo-
tinib (Nil), applied with 200 ng/mL recombinant human stem cell factor (rh SCF). Cells were cul-
tured in RPMI 1640 medium supplemented with 10% v/v FBS and 1% v/v penicillin-streptomycin
solution, and maintained in a humidified incubator containing 5% CO2 at 37º C for 48 hours before
the assay. In the graph, black shaded bars represent the cell viability (%), whereas white shaded
bars denote the viable cell number (1 x 106 cells/mL). P-values for cell viability were calculated
in the test pair labeled 3 and 7, and pair 4 and 8 to compare a combinatorial treatment versus one
drug solution. In the treatment annotation table below the graph, a dash (-) stands for the absence
of the corresponding treatment factor. For example, the first column with 3 dashes corresponds to
a null condition, i.e., without an antibody, SCF, or drug.
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Figure 6.20: Viability Assay for JURL-MK1 Cells in a Combination of Apo A1 IgG and
Nilotinib Treatments. The combinatorial treatment consists of 3 μg/mL Apo A1 IgG and 30
nM nilotinib (Nil), applied with 200 ng/mL recombinant human stem cell factor (rh SCF). Cells
were cultured in RPMI 1640 medium supplemented with 10% v/v FBS and 1% v/v penicillin-
streptomycin solution, and maintained in a humidified incubator containing 5% CO2 at 37º C for
48 hours before the assay. In the graph, black shaded bars represent the cell viability (%), whereas
white shaded bars denote the viable cell number (1 x 106 cells/mL). P-values for cell viability were
calculated in the test pair labeled 3 and 7, and pair 4 and 8 to compare a combinatorial treatment
versus one drug solution. In the treatment annotation table below the graph, a dash (-) stands for
the absence of the corresponding treatment factor.
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Figure 6.21: Viability Assay for JURL-MK1 Cells in a Combination of Apo A2 IgG and
Nilotinib Treatments. The combinatorial treatment consists of 3 μg/mL Apo A2 IgG and 30
nM nilotinib (Nil), applied with 200 ng/mL recombinant human stem cell factor (rh SCF). Cells
were cultured in RPMI 1640 medium supplemented with 10% v/v FBS and 1% v/v penicillin-
streptomycin solution, and maintained in a humidified incubator containing 5% CO2 at 37º C for
48 hours before the assay. In the graph, black shaded bars represent the cell viability (%), whereas
white shaded bars denote the viable cell number (1 x 106 cells/mL). P-values for cell viability were
calculated in the test pair labeled 3 and 7, and pair 4 and 8 to compare a combinatorial treatment
versus one drug solution. In the treatment annotation table below the graph, a dash (-) stands for
the absence of the corresponding treatment factor.
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6.4.2 Data Analysis and Discussion: By Successfully Inhibiting the c-Kit Pathway,
the sABs Induced Increased Cell Deaths
In all cases with the presence of SCF, both cell viability and cell number increased compared
to those respective values in the absence of SCF condition. SCF is a cytokine that provides a
protective effect occurred through the SCF signaling on the BCR-ABL and c-Kit expressing cells.
This means the presence of SCF condition is able to compensate for the BCR-ABL inhibition
in CML cells. In other words, the environmental presentation of SCF supports the survival of
CML cells by partially rescuing them from the nilotinib activity. Hence, by reversing a protective
effect from the SCF condition, a combination of sABs and nilotinib promotes more cell death by
simultaneously targeting both c-Kit and BCR-ABL pathways. As such, it is vital to block the SCF-
mediated innate resistance, in order to develop an effective strategy for improved CML treatment,
which is one of the proposed signal-pathway approaches in this thesis.
Indeed, for cases with SCF condition, it is still possible to induce cell death with an appropri-
ately designed combination of drug and sABs, which specifically target the c-Kit pathway. In fact,
Figure 6.18 demonstrates this phenomenon, where even with an addition of SCF, a suitable com-
bination of sABs and nilotinib treatments significantly reduced cell viability and cell number. In
other words, the obtained data suggest that a specifically designed combination of sABs and nilo-
tinib treatments may act in synergy to promote more significant cell death compared to a single
drug application alone.
It should be noted that, to ensure repeatability and consistency of data, a triplicate setup was
performed. The corresponding error bars are statistically small in size, and do not overlap between
associated pairs of test scenarios. In addition, for cell viability assay with the developed sABs, the
data indicate that KU-812 was the most compatible cell line, with the lowest cell viability and cell
number values, consistently across all c-Kit antibodies.
In brief, cell viability assay on various CML cell lines showed that SCF treatment reduced the
activity of nilotinib drug, but this drug activity could be restored by co-treating cells with c-Kit
antibodies.
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6.5 Apoptosis Assay: Examination of Nilotinib Apoptotic Effect Using a
Combinatorial Treatment
The cell viability assay performed in the previous section substantiates that the proposed com-
binatorial approach promotes cell death more significantly compared to a single drug application
alone, but it is unable to specifically identify the effects of apoptosis, which is a biochemical
process causing programmed cell death that is particularly relevant for this research. From a ther-
apeutic perspective, the combinatorial treatment should be designed to induce apoptosis, in order
to eliminate the cancer cells of interest. Therefore, to investigate the treatment effectiveness, an
apoptosis assay should be performed. This assay measures the apoptotic effect of CML cells in
response to a combinatorial treatment in two different cases, i.e., in the presence and absence of
SCF. Then, by comparing the results from these two cases, it can be determined whether a majority
of the cell deaths can indeed be ascribed to the applied combinatorial treatment.
In particular, since apoptosis causes death by inducing characteristic cellular changes, an ap-
propriate assay may be designed to detect these effects. Such effects include: a) loss of plasma
membrane asymmetry and attachment; b) cytoplasmic and nuclear condensation; and c) chromatin
degradation. Importantly, the loss of membrane integrity occurs in the early stage of apoptosis.
Therefore, the assay in this section is designed to target this loss of membrane in order to quantify
the apoptotic effect [113, 114].
The apoptosis assay involves Annexin V staining and flow cytometric analysis of cells in or-
der to detect this morphological change. Specifically, the phospholipid phosphatidylserine (PS),
normally hidden in the inner layer of the plasma membrane, is translocated to the outer leaflet of
the membrane, thereby exposing PS on the cellular surface. As such, Annexin V is used to bind
to apoptotic cells with this exposed PS on the external cellular environment. This is feasible be-
cause this Annexin V is a 35-36 kDa Ca2+ dependent phospholipid-binding protein that has a high
affinity for PS, which in turn makes it a sensitive probe to perform flow cytometric analysis.
In addition, it should be noted that Annexin V is conjugated to a fluorochrome such as FITC,
PE, and allophycocyanin conjugate (APC) to distinguish cells in the early stage of apoptosis, and
the stain is typically used in conjunction with a vital dye (e.g., sytox blue or propidium iodide (PI))
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to identify dead and damaged cells in the late stage of apoptosis. As will be reported in the sub-
sequent results, the relevant fluorochromes for this research are FITC and APC, for distinguishing
cells in the early stage of apoptosis, used in conjunction with either sytox blue or PI as necessary,
for identifying dead and damaged cells in the late stage of apoptosis.
6.5.1 Data for Apoptosis Assay with CML Cell Lines
The initial steps of this experiment are similar to those in the cell viability assay, consisting
of appropriate preparation and incubation criteria as described in Section 4.3.5. Then, Annexin
V staining was performed in accordance with the manufacturer’s instructions to enable apoptosis
analysis using flow cytometry, with each test scenario in triplicate for all CML cell lines. Once
the flow cytometric results were obtained, FlowJo Version 8.8.7 was utilized to generate analytical
data for the following graphs, presented according to cell line:
• CJ: results shown in Figures 6.22–6.24;
• KU-812: results shown in Figures 6.25–6.27;
• JURL-MK1: results shown in Figures 6.28–6.30.
As in the cell viability test in Section 6.4, each combination consists of a drug and an sAB co-
agent, along with the presence or absence of SCF investigated. However, instead of the number
of general cell deaths due to various causes, the flow cytometric measurements assess this death
quantity specifically due to apoptosis in this case. For statistical validation, the one-tailed Student’s
t-test was used to specifically compare pairs of test scenarios consisting of a drug application alone
versus a combinatorial therapy, with and without SCF conditions, thus generating corresponding
p-values for statistical significance testing.
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Figure 6.22: Apoptosis Assay for CJ Cells in a Combination of Apo A IgG and Nilotinib
Treatments. The combinatorial treatment consists of 3 μg/mL Apo A IgG and 50 nM nilotinib
(Nil), applied with 200 ng/mL recombinant mouse stem cell factor (rm SCF). Cells were cultured
in RPMI 1640 medium supplemented with 20% v/v FBS, and maintained in a humidified incubator
containing 5% CO2 at 37º C for 40 hours before the assay. In the graph, green shaded bars are used
to specify an absence of SCF, whereas purple shaded bars indicate a presence of SCF. P-values
for apoptosis (%) were calculated in the test pair labeled 3 and 7, and pair 4 and 8 to compare
a combinatorial treatment versus one drug solution. In the treatment annotation table below the
graph, a dash (-) stands for the absence of the corresponding treatment factor. For example, the
first column with 3 dashes corresponds to a null condition, i.e., without an antibody, SCF, or drug.
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Figure 6.23: Apoptosis Assay for CJ Cells in a Combination of Apo A1 IgG and Nilotinib
Treatments. The combinatorial treatment consists of 3 μg/mL Apo A1 IgG and 50 nM nilotinib
(Nil), applied with 200 ng/mL recombinant mouse stem cell factor (rm SCF). Cells were cultured
in RPMI 1640 medium supplemented with 20% v/v FBS, and maintained in a humidified incubator
containing 5% CO2 at 37º C for 40 hours before the assay. In the graph, green shaded bars are used
to specify an absence of SCF, whereas purple shaded bars indicate a presence of SCF. P-values
for apoptosis (%) were calculated in the test pair labeled 3 and 7, and pair 4 and 8 to compare
a combinatorial treatment versus one drug solution. In the treatment annotation table below the
graph, a dash (-) stands for the absence of the corresponding treatment factor.
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Figure 6.24: Apoptosis Assay for CJ Cells in a Combination of Apo A2 IgG and Nilotinib
Treatments. The combinatorial treatment consists of 3 μg/mL Apo A2 IgG and 50 nM nilotinib
(Nil), applied with 200 ng/mL recombinant mouse stem cell factor (rm SCF). Cells were cultured
in RPMI 1640 medium supplemented with 20% v/v FBS, and maintained in a humidified incubator
containing 5% CO2 at 37º C for 40 hours before the assay. In the graph, green shaded bars are used
to specify an absence of SCF, whereas purple shaded bars indicate a presence of SCF. P-values
for apoptosis (%) were calculated in the test pair labeled 3 and 7, and pair 4 and 8 to compare
a combinatorial treatment versus one drug solution. In the treatment annotation table below the
graph, a dash (-) stands for the absence of the corresponding treatment factor.
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Figure 6.25: Apoptosis Assay for KU-812 Cells in a Combination of Apo A IgG and Nilotinib
Treatments. The combinatorial treatment consists of 3 μg/mL Apo A IgG and 10 nM nilotinib
(Nil), applied with 200 ng/mL recombinant human stem cell factor (rh SCF). Cells were cultured in
RPMI 1640 medium supplemented with 10% v/v FBS and 1% v/v penicillin-streptomycin solution,
and maintained in a humidified incubator containing 5% CO2 at 37º C for 48 hours before the assay.
In the graph, green shaded bars are used to specify an absence of SCF, whereas purple shaded bars
indicate a presence of SCF. P-values for apoptosis (%) were calculated in the test pair labeled 3 and
7, and pair 4 and 8 to compare a combinatorial treatment versus one drug solution. In the treatment
annotation table below the graph, a dash (-) stands for the absence of the corresponding treatment
factor. For example, the first column with 3 dashes corresponds to a null condition, i.e., without an
antibody, SCF, or drug.
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Figure 6.26: Apoptosis Assay for KU-812 Cells in a Combination of Apo A1 IgG and Nilotinib
Treatments. The combinatorial treatment consists of 3 μg/mL Apo A1 IgG and 10 nM nilotinib
(Nil), applied with 200 ng/mL recombinant human stem cell factor (rh SCF). Cells were cultured in
RPMI 1640 medium supplemented with 10% v/v FBS and 1% v/v penicillin-streptomycin solution,
and maintained in a humidified incubator containing 5% CO2 at 37º C for 48 hours before the assay.
In the graph, green shaded bars are used to specify an absence of SCF, whereas purple shaded bars
indicate a presence of SCF. P-values for apoptosis (%) were calculated in the test pair labeled 3 and
7, and pair 4 and 8 to compare a combinatorial treatment versus one drug solution. In the treatment
annotation table below the graph, a dash (-) stands for the absence of the corresponding treatment
factor.
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Figure 6.27: Apoptosis Assay for KU-812 Cells in a Combination of Apo A2 IgG and Nilotinib
Treatments. The combinatorial treatment consists of 3 μg/mL Apo A2 IgG and 10 nM nilotinib
(Nil), applied with 200 ng/mL recombinant human stem cell factor (rh SCF). Cells were cultured in
RPMI 1640 medium supplemented with 10% v/v FBS and 1% v/v penicillin-streptomycin solution,
and maintained in a humidified incubator containing 5% CO2 at 37º C for 48 hours before the assay.
In the graph, green shaded bars are used to specify an absence of SCF, whereas purple shaded bars
indicate a presence of SCF. P-values for apoptosis (%) were calculated in the test pair labeled 3 and
7, and pair 4 and 8 to compare a combinatorial treatment versus one drug solution. In the treatment
annotation table below the graph, a dash (-) stands for the absence of the corresponding treatment
factor.
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Figure 6.28: Apoptosis Assay for JURL-MK1 Cells in a Combination of Apo A IgG and Nilo-
tinib Treatments. The combinatorial treatment consists of 3 μg/mL Apo A IgG and 30 nM nilo-
tinib (Nil), applied with 200 ng/mL recombinant human stem cell factor (rh SCF). Cells were cul-
tured in RPMI 1640 medium supplemented with 10% v/v FBS and 1% v/v penicillin-streptomycin
solution, and maintained in a humidified incubator containing 5% CO2 at 37º C for 48 hours be-
fore the assay. In the graph, green shaded bars are used to specify an absence of SCF, whereas
purple shaded bars indicate a presence of SCF. P-values for apoptosis (%) were calculated in the
test pair labeled 3 and 7, and pair 4 and 8 to compare a combinatorial treatment versus one drug
solution. In the treatment annotation table below the graph, a dash (-) stands for the absence of the
corresponding treatment factor. For example, the first column with 3 dashes corresponds to a null
condition, i.e., without an antibody, SCF, or drug.
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Figure 6.29: Apoptosis Assay for JURL-MK1 Cells in a Combination of Apo A1 IgG and
Nilotinib Treatments. The combinatorial treatment consists of 3 μg/mL Apo A1 IgG and 30
nM nilotinib (Nil), applied with 200 ng/mL recombinant human stem cell factor (rh SCF). Cells
were cultured in RPMI 1640 medium supplemented with 10% v/v FBS and 1% v/v penicillin-
streptomycin solution, and maintained in a humidified incubator containing 5% CO2 at 37º C for
48 hours before the assay. In the graph, green shaded bars are used to specify an absence of SCF,
whereas purple shaded bars indicate a presence of SCF. P-values for apoptosis (%) were calculated
in the test pair labeled 3 and 7, and pair 4 and 8 to compare a combinatorial treatment versus one
drug solution. In the treatment annotation table below the graph, a dash (-) stands for the absence
of the corresponding treatment factor.
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Figure 6.30: Apoptosis Assay for JURL-MK1 Cells in a Combination of Apo A2 IgG and
Nilotinib Treatments. The combinatorial treatment consists of 3 μg/mL Apo A2 IgG and 30
nM nilotinib (Nil), applied with 200 ng/mL recombinant human stem cell factor (rh SCF). Cells
were cultured in RPMI 1640 medium supplemented with 10% v/v FBS and 1% v/v penicillin-
streptomycin solution, and maintained in a humidified incubator containing 5% CO2 at 37º C for
48 hours before the assay. In the graph, green shaded bars are used to specify an absence of SCF,
whereas purple shaded bars indicate a presence of SCF. P-values for apoptosis (%) were calculated
in the test pair labeled 3 and 7, and pair 4 and 8 to compare a combinatorial treatment versus one
drug solution. In the treatment annotation table below the graph, a dash (-) stands for the absence
of the corresponding treatment factor.
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6.5.2 Data Analysis and Discussion: By Blocking the Innate Resistance, the sABs
Promoted Nilotinib Apoptotic Activity
In all cases with the presence of SCF, apoptotic activity quantified by percentage values de-
creased compared to those respective values in the absence of SCF condition (e.g., see Figure 6.25).
This means that the addition of SCF reduces drug effect, in partially rescuing the cells from the
nilotinib treatment, but this effect can be counteracted with an appropriate sAB co-agent. There-
fore, from an apoptotic perspective, the rationale for blocking the SCF-mediated innate resistance
is reaffirmed for CML treatment. This can be achieved by inhibiting the corresponding receptor
c-Kit in order to suppress the pathway responsible for this innate resistance.
As in the cell viability assay, a triplicate setup was performed to enable data consistency. Also,
the obtained error bars do not overlap between associated pairs of test scenarios. In addition,
according to the apoptosis assay with the developed sABs, the data suggest that Apo A IgG and
Apo A2 IgG should be the preferred candidates, since they induced the highest apoptotic activity
with all CML cell lines investigated.
All in all, compatible with all the tests conducted so far, apoptosis assay also demonstrated that,
even though SCF stimulation hindered nilotinib in treating CML, this challenge may be overcome
by recruiting a suitable ally in the form of c-Kit antibody co-agents.
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6.6 Colony Forming Cell (CFC) Assay: Investigation of the Progenitor Abil-
ity of CML Cells Using a Combinatorial Approach
The tests conducted thus far focused on various aspects of the cells within their individual life
cycle, e.g., cell death and apoptosis. However, cancer development involves more than just inde-
pendent behavior of the cells in isolation. For instance, among some well known hallmarks, cancer
cells exhibit the ability to affect other cells or to reproduce progenies with anomalous character-
istics, as well as resistance to drug treatment and relapse occurrence [115, 116]. In fact, it is now
known that many cancers are able to sustain these characteristics via specialized entities known
as the progenitor cells [13, 117]. Clearly, in developing suitable cancer therapy, it is important to
understand the effects of the treatment on these progenitor cells to completely suppress the dis-
ease. Therefore, last but not least, a test that is able to assess the status of these progenitor cells is
immensely relevant here. To this end, since a characteristic behavior of the progenitor cells is that
they proliferate and differentiate into colonies, a corresponding colony forming cell (CFC) assay
can be applied to measure this phenomenon in order to quantify the progenitor ability.
Procedurally, the CFC assay involves using various cytokines to stimulate growth in a methyl-
cellulose-based medium to form colonies. This means that the number of progenitor cells can be
enumerated by counting the number of colonies under an inverted microscope. Then, this assay
allows for investigating how a combinatorial drug treatment affects progenitor cells. In particular,
for a successful drug combination, it is expected that the number of colonies should be significantly
decreased when the treatment is applied.
6.6.1 Data for CFC Assay with CML Cell Lines
Fundamentally, CFC assay is a cell counting technique without staining, which means that
it is most similar to cell viability assay in Section 6.4, and as such, also necessitates similar
initial preparation steps as described in Section 4.3.6. Colony formation was quantitated using
MethoCult™ methylcellulose-based medium in accordance with the manufacturer’s instructions.
However, within methylcellulose-based medium, the progenitor cells require sufficient time to dif-
ferentiate into visually distinguishable clusters. In particular, the incubation time is significantly
longer compared to other tests, ranging from 7–14 days in a humidified incubator containing 5%
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CO2 at 37º C before quantifying the resulting colonies under an inverted microscope. This test is
therefore highly time-consuming, resource demanding (i.e., costly) and attention-intensive.
The obtained CFC assay data are grouped according to cell line in the following graphs:
• CJ: results shown in Figures 6.31–6.33;
• KU-812: results shown in Figures 6.34–6.36;
• JURL-MK1: results shown in Figures 6.37–6.39.
As already noted, this technique is related to cell viability assay and it also has similar output
format, with one crucial difference, i.e., the histograms depicting the number of colonies instead
of the number of cells.
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Figure 6.31: Colony Forming Cell Assay for CJ Cells in a Combination of Apo A IgG and
Nilotinib Treatments. The combinatorial treatment consists of 3 μg/mL Apo A IgG and 50 nM
nilotinib (Nil), applied with 200 ng/mL recombinant mouse stem cell factor (rm SCF). Cells were
first prepared in RPMI 1640 medium supplemented with 20% v/v FBS, and maintained in a hu-
midified incubator containing 5% CO2 at 37º C for 40 hours before the CFC assay setup. Next,
cells were then cultured in MethoCult™ GF M3434 methylcellulose medium, and maintained in a
humidified incubator for 7-14 days. In the graph, white bars are used to specify an absence of SCF,
whereas black shaded bars indicate a presence of SCF. P-values for colony number were calculated
in the test pair labeled 3 and 7, and pair 4 and 8 to compare a combinatorial treatment versus one
drug solution. In the treatment annotation table below the graph, a dash (-) stands for the absence
of the corresponding treatment factor. For example, the first column with 3 dashes corresponds to
a null condition, i.e., without an antibody, SCF, or drug.
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Figure 6.32: Colony Forming Cell Assay for CJ Cells in a Combination of Apo A1 IgG and
Nilotinib Treatments. The combinatorial treatment consists of 3 μg/mL Apo A1 IgG and 50
nM nilotinib (Nil), applied with 200 ng/mL recombinant mouse stem cell factor (rm SCF). Cells
were first prepared in RPMI 1640 medium supplemented with 20% v/v FBS, and maintained in a
humidified incubator containing 5% CO2 at 37º C for 40 hours before the CFC assay setup. Next,
cells were then cultured in MethoCult™ GF M3434 methylcellulose medium, and maintained in a
humidified incubator for 7-14 days. In the graph, white bars are used to specify an absence of SCF,
whereas black shaded bars indicate a presence of SCF. P-values for colony number were calculated
in the test pair labeled 3 and 7, and pair 4 and 8 to compare a combinatorial treatment versus one
drug solution. In the treatment annotation table below the graph, a dash (-) stands for the absence
of the corresponding treatment factor.
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Figure 6.33: Colony Forming Cell Assay for CJ Cells in a Combination of Apo A2 IgG and
Nilotinib Treatments. The combinatorial treatment consists of 3 μg/mL Apo A2 IgG and 50
nM nilotinib (Nil), applied with 200 ng/mL recombinant mouse stem cell factor (rm SCF). Cells
were first prepared in RPMI 1640 medium supplemented with 20% v/v FBS, and maintained in a
humidified incubator containing 5% CO2 at 37º C for 40 hours before the CFC assay setup. Next,
cells were then cultured in MethoCult™ GF M3434 methylcellulose medium, and maintained in a
humidified incubator for 7-14 days. In the graph, white bars are used to specify an absence of SCF,
whereas black shaded bars indicate a presence of SCF. P-values for colony number were calculated
in the test pair labeled 3 and 7, and pair 4 and 8 to compare a combinatorial treatment versus one
drug solution. In the treatment annotation table below the graph, a dash (-) stands for the absence
of the corresponding treatment factor.
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Figure 6.34: Colony Forming Cell Assay for KU-812 Cells in a Combination of Apo A IgG
and Nilotinib Treatments. The combinatorial treatment consists of 3 μg/mL Apo A IgG and 10
nM nilotinib (Nil), applied with 200 ng/mL recombinant human stem cell factor (rh SCF). Cells
were first prepared in RPMI 1640 medium supplemented with 10% v/v FBS and 1% v/v penicillin-
streptomycin solution, and maintained in a humidified incubator containing 5% CO2 at 37º C C
for 48 hours before the CFC assay setup. Next, cells were then cultured in MethoCult™ H4434
methylcellulose medium, and maintained in a humidified incubator for 7-14 days. In the graph,
white bars are used to specify an absence of SCF, whereas black shaded bars indicate a presence
of SCF. P-values for colony number were calculated in the test pair labeled 3 and 7, and pair 4
and 8 to compare a combinatorial treatment versus one drug solution. In the treatment annotation
table below the graph, a dash (-) stands for the absence of the corresponding treatment factor. For
example, the first column with 3 dashes corresponds to a null condition, i.e., without an antibody,
SCF, or drug.
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Figure 6.35: Colony Forming Cell Assay for KU-812 Cells in a Combination of Apo A1 IgG
and Nilotinib Treatments. The combinatorial treatment consists of 3 μg/mL Apo A1 IgG and 10
nM nilotinib (Nil), applied with 200 ng/mL recombinant human stem cell factor (rh SCF). Cells
were first prepared in RPMI 1640 medium supplemented with 10% v/v FBS and 1% v/v penicillin-
streptomycin solution, and maintained in a humidified incubator containing 5% CO2 at 37º C for
48 hours before the CFC assay setup. Next, cells were then cultured in MethoCult™ H4434
methylcellulose medium, and maintained in a humidified incubator for 7-14 days. In the graph,
white bars are used to specify an absence of SCF, whereas black shaded bars indicate a presence
of SCF. P-values for colony number were calculated in the test pair labeled 3 and 7, and pair 4 and
8 to compare a combinatorial treatment versus one drug solution. In the treatment annotation table
below the graph, a dash (-) stands for the absence of the corresponding treatment factor.
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Figure 6.36: Colony Forming Cell Assay for KU-812 Cells in a Combination of Apo A2 IgG
and Nilotinib Treatments. The combinatorial treatment consists of 3 μg/mL Apo A2 IgG and 10
nM nilotinib (Nil), applied with 200 ng/mL recombinant human stem cell factor (rh SCF). Cells
were first prepared in RPMI 1640 medium supplemented with 10% v/v FBS and 1% v/v penicillin-
streptomycin solution, and maintained in a humidified incubator containing 5% CO2 at 37º C for
48 hours before the CFC assay setup. Next, cells were then cultured in MethoCult™ H4434
methylcellulose medium, and maintained in a humidified incubator for 7-14 days. In the graph,
white bars are used to specify an absence of SCF, whereas black shaded bars indicate a presence
of SCF. P-values for colony number were calculated in the test pair labeled 3 and 7, and pair 4 and
8 to compare a combinatorial treatment versus one drug solution. In the treatment annotation table
below the graph, a dash (-) stands for the absence of the corresponding treatment factor.
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Figure 6.37: Colony Forming Cell Assay for JURL-MK1 Cells in a Combination of
Apo A IgG and Nilotinib Treatments. The combinatorial treatment consists of 3 μg/mL Apo
A IgG and 30 nM nilotinib (Nil), applied with 200 ng/mL recombinant human stem cell factor (rh
SCF). Cells were first prepared in RPMI 1640 medium supplemented with 10% v/v FBS and 1%
v/v penicillin-streptomycin solution, and maintained in a humidified incubator containing 5% CO2
at 37º C for 48 hours before the CFC assay setup. Next, cells were then cultured in MethoCult™
H4434 methylcellulose medium, and maintained in a humidified incubator for 7-14 days. In the
graph, white bars are used to specify an absence of SCF, whereas black shaded bars indicate a pres-
ence of SCF. P-values for colony number were calculated in the test pair labeled 3 and 7, and pair
4 and 8 to compare a combinatorial treatment versus one drug solution. In the treatment annotation
table below the graph, a dash (-) stands for the absence of the corresponding treatment factor. For
example, the first column with 3 dashes corresponds to a null condition, i.e., without an antibody,
SCF, or drug.
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Figure 6.38: Colony Forming Cell Assay for JURL-MK1 Cells in a Combination of
Apo A1 IgG and Nilotinib Treatments. The combinatorial treatment consists of 3 μg/mL Apo
A1 IgG and 30 nM nilotinib (Nil), applied with 200 ng/mL recombinant human stem cell factor (rh
SCF). Cells were first prepared in RPMI 1640 medium supplemented with 10% v/v FBS and 1%
v/v penicillin-streptomycin solution, and maintained in a humidified incubator containing 5% CO2
at 37º C for 48 hours before the CFC assay setup. Next, cells were then cultured in MethoCult™
H4434 methylcellulose medium, and maintained in a humidified incubator for 7-14 days. In the
graph, white bars are used to specify an absence of SCF, whereas black shaded bars indicate a pres-
ence of SCF. P-values for colony number were calculated in the test pair labeled 3 and 7, and pair
4 and 8 to compare a combinatorial treatment versus one drug solution. In the treatment annotation
table below the graph, a dash (-) stands for the absence of the corresponding treatment factor.
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Figure 6.39: Colony Forming Cell Assay for JURL-MK1 Cells in a Combination of
Apo A2 IgG and Nilotinib Treatments. The combinatorial treatment consists of 3 μg/mL Apo
A2 IgG and 30 nM nilotinib (Nil), applied with 200 ng/mL recombinant human stem cell factor (rh
SCF). Cells were first prepared in RPMI 1640 medium supplemented with 10% v/v FBS and 1%
v/v penicillin-streptomycin solution, and maintained in a humidified incubator containing 5% CO2
at 37º C for 48 hours before the CFC assay setup. Next, cells were then cultured in MethoCult™
H4434 methylcellulose medium, and maintained in a humidified incubator for 7-14 days. In the
graph, white bars are used to specify an absence of SCF, whereas black shaded bars indicate a pres-
ence of SCF. P-values for colony number were calculated in the test pair labeled 3 and 7, and pair
4 and 8 to compare a combinatorial treatment versus one drug solution. In the treatment annotation
table below the graph, a dash (-) stands for the absence of the corresponding treatment factor.
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6.6.2 Data Analysis and Discussion: the Combinatorial Approach Has the Potential
to Eliminate Progenitor Cells
A general observation reveals that, for all graphs, the number of colonies for all test scenarios
significantly decreased when a combinatorial approach is applied. More specifically, this decrease
is quantified by p-values less than 10-4 in a significance test between a combinatorial approach and
the reference case of drug application alone (e.g., compare test pair labeled 3 and 7 or pair 4 and
8 in Figure 6.34, corresponding to KU-812 cells, in absence and presence of SCF). Therefore, a
suitable drug combination has the potential to mitigate the progenitor effect. Furthermore, in all
cases, the associated error bars are non-overlapping, reinforcing the count consistency for result
reproducibility.
More specifically, focusing on more individual comparisons, it can be seen the decrease profiles
do exhibit variations across different cell lines. For example, after treatment, a human CML cell
line (e.g., KU-812) showed more differentiated clusters compared to a murine CML cell line (e.g.,
CJ). This implies that the progenitor cells respond differently to the cytokine stimulation, and have
different susceptibility to therapy. But despite these varying responses under different operating
conditions, the overall trend is maintained: for any particular cell line, relative to the control case
with drug application alone, a combinatorial treatment leads to a decrease in colonies formed.
Taken together, the results obtained from CFC assays confirm that a properly designed com-
binatorial treatment has a promising potential to diminish the progenitor capacity, and that this
potential may be realized for various operating conditions with different cell lines. And as pre-
viously noted, since progenitor cells are responsible for a number of hallmark characteristics in
cancer — most notably drug resistance and relapse — the flexible approach of combinatorial treat-
ment, which allows for attenuating the progenitor effect in various scenarios, represents indeed a
promising and desirable paradigm for cancer therapy development.
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7. Conclusion
This chapter summarizes the contributions and outline directions for future research.
7.1 Summary of Contributions and Main Results
In this thesis, the problem of innate resistance mediated by SCF signaling in CML is investi-
gated. Specifically, the focus is on the disruption of nilotinib apoptotic activity due to the SCF/c-Kit
signaling pathway, which protects the primitive population of CML cells implicated in innate re-
sistance, i.e., the quiescent LSCs found in the bone marrow endosteal niche, where hematopoietic
cytokines such as the ligand SCF are released.
To this end, a combinatorial strategy based on sABs is proposed to inhibit the receptor c-
Kit, thus blocking the innate resistance and restoring nilotinib apoptotic activity. In particular, by
exploiting the knowledge of c-Kit vulnerability, the sABs are designed based on antibody phage
display technology to specifically target D1–D3 domains representing the SCF binding sites for
pathway activation.
To assess the performance of the proposed strategy, a set of in vitro tests was conducted, focus-
ing on performance behaviors such as cell binding, cell death, and the progenitor ability. Figure
7.1 provides an overall summary of the combinatorial treatment and main results. Notably, the
obtained in vitro results demonstrate that:
• Based on cell binding tests, the sAB co-agents produced exhibit high affinity and strong
binding specificity across various human and murine CML cell lines;
• Based on cell viability and apoptosis assays, the sAB co-agents have the potential to restore
nilotinib induced apoptosis, resulting in significantly reduced cell viability.
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Figure 7.1: Overall Summary of the Combinatorial Treatment (Nilotinib and sABs) and
Main Findings. 1) The proposed strategy: the sABs are designed using phage display technology
to specifically target D1–D3 domains of the receptor c-Kit, with the goal of inhibiting the SCF/c-
Kit pathway, in order to block the innate resistance and restore nilotinib activity; 2) Experimental
findings: according to tissue culture assays, the sAB co-agents indeed have the potential to restore
nilotinib induced apoptosis, and mitigate the proliferation and differentiation of hematopoietic
progenitors.
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• Based on the CFC assay, the sAB co-agents have the potential to mitigate the proliferation
and differentiation of hematopoietic progenitors.
Altogether, these resulting research findings validate the hypothesis that a specifically designed
combination of a BCR-ABL drug (i.e., Nilotinib) and an sAB co-agent (i.e., anti–c-Kit sAB)
inhibiting the SCF/c-Kit pathway should be effective in mitigating the proliferating LSCs, thus
providing a potential means to achieve a CML curative paradigm [5, 21].
7.2 Future Research Directions
In contemplating directions for potential future research, the following feasible methods and
open problems may be considered in order to better illuminate and vindicate the proposed thera-
peutic strategy.
• So far, only in vitro testing has been performed in this thesis. For therapy development,
the ultimate goal is to achieve clinically significant results in patients. To this end, in vivo
testing should be pursued, which allows for investigating performance issues that may not
be measurable using in vitro experiments within a lab environment. By extension, once in
vivo testing produces promising results, patient testing would ensue.
• To improve the performance results, i.e., achieving higher efficiency, the methodology should
be extended.
1. If limited to a two-agent combination, it is possible to consider different BCR-ABL
drugs (e.g., bosutinib or ponatinib with supposedly better performance) in conjunction
with other possible sABs. Because different agents are utilized, this approach is ex-
pected to generate different performance; however, it is inherently constrained and not
necessarily guaranteed to produce significant improvement.
2. Alternatively, allowing for a multi-agent combination, it is feasible to further enhance
synergy with multiple drugs and/or sABs. While this approach should offer more
promising performance gains, there are also important caveats to heed, since the ap-
proach is actually contingent on a judicious selection of agents, which should be com-
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plementary in order to realize the synergistic potential. In fact, if unapt agents, with
antagonistic properties, are selected, the combinatorial approach may be invalidated.
• Almost serendipitously, in allowing for a multi-agent approach to initially enhance effec-
tiveness, an additional benefit may be realized. Indeed, more interestingly, the approach also
paves the way for addressing the multifactorial phenomenon of innate resistance, which may
be due to multiple pathways [14]. This is because inhibition of a specific signaling pathway,
e.g., c-Kit pathway, may be compensated by bone marrow cytokine stimulation of alternative
and interacting pathways. For instance, alternative pathways may include cytokine pathways
mediated by stromal factors such as interleukin-3 or insulin-like growth factor 1 [118–120].
In other words, while a panacea may not be practically attainable, at least this multi-agent
solution should have the potential to address the different aspects of the multifactorial in-
nate resistance, e.g., similar to the solution strategy proposed for the SCF-mediated innate
resistance in this thesis, an sAB may be designed to specifically target a particular aspect
of the multifactorial phenomenon. This in turn also implies future investigation of suitable
domains for antibody binding in order to deactivate these different constituent pathways.
• Last but not least, with respect to long-term vision, the applicability of the proposed com-
binatorial therapy may be considered for other cancers and, by extension, for other diseases
also. In particular, this vision should be germane to cancers driven by cancer stem cells,
which exhibit the hallmarks of resiliency and mutability in resisting drug treatment [115].
Therefore, a suitable therapy platform should have sufficient versatility and diversity in order
to counterattack this insidious challenge, i.e., similar to the versatile platform proposed in
this thesis, in which a combinatorial strategy consisting of suitable co-agents demonstrates a
significant potential to counteract the c-Kit pathway and mitigate the innate resistance.
108
References
[1] J. Cortes and M. Deininger, eds., Chronic Myeloid Leukemia. New York, NY: Informa
Healthcare, 2007.
[2] B. A. Burke and M. Carroll, “BCR-ABL: a multi-faceted promoter of DNA mutation in
chronic myelogeneous leukemia,” Leukemia, vol. 24, pp. 1105–12, June 2010.
[3] N. C. P. Cross, G. Q. Daley, A. R. Green, T. P. Hughes, C. Jamieson, P. Manley, T. Mughal,
D. Perrotti, J. Radich, R. Skoda, S. Soverini, W. Vainchenker, S. Verstovsek, J.-L. Vill-
eval, and J. M. Goldman, “BCR-ABL1-positive CML and BCR-ABL1-negative chronic
myeloproliferative disorders: some common and contrasting features,” Leukemia, vol. 22,
pp. 1975–89, Nov. 2008.
[4] A. S. Shet, B. N. Jahagirdar, and C. M. Verfaillie, “Chronic myelogenous leukemia: mech-
anisms underlying disease progression,” Leukemia, vol. 16, pp. 1402–11, Aug. 2002.
[5] B. Clarkson, A. Strife, D. Wisniewski, C. L. Lambek, and C. Liu, “Chronic myelogenous
leukemia as a paradigm of early cancer and possible curative strategies,” Leukemia, vol. 17,
pp. 1211–62, July 2003.
[6] R. Hehlmann, A. Hochhaus, and M. Baccarani, “Chronic myeloid leukaemia,” The Lancet,
vol. 370, pp. 342–350, Aug. 2007.
[7] D. Bixby and M. Talpaz, “Seeking the causes and solutions to imatinib-resistance in chronic
myeloid leukemia,” Leukemia, vol. 25, pp. 7–22, Jan. 2011.
[8] F. J. Giles, M. O’Dwyer, and R. Swords, “Class effects of tyrosine kinase inhibitors in the
treatment of chronic myeloid leukemia,” Leukemia, vol. 23, pp. 1698–707, Oct. 2009.
[9] P. J. Shami and M. Deininger, “Evolving treatment strategies for patients newly diagnosed
with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-
line therapy,” Leukemia, vol. 26, pp. 214–24, Feb. 2012.
109
[10] N. P. Shah, F. Guilhot, J. E. Cortes, C. A. Schiffer, P. le Coutre, T. H. Bru¨mmendorf,
H. M. Kantarjian, A. Hochhaus, P. Rousselot, H. Mohamed, D. Healey, M. Cunningham,
and G. Saglio, “Long-term outcome with dasatinib after imatinib failure in chronic-phase
chronic myeloid leukemia: follow-up of phase 3 study,” Blood, pp. 2317–2324, Feb. 2014.
[11] C. C. Smith and N. P. Shah, “Tyrosine kinase inhibitor therapy for chronic myeloid
leukemia: approach to patients with treatment-naive or refractory chronic-phase disease,”
Hematology / the Education Program of the American Society of Hematology. American
Society of Hematology. Education Program, vol. 2011, pp. 121–7, Jan. 2011.
[12] M. Breccia and G. Alimena, “Discontinuation of tyrosine kinase inhibitors and new ap-
proaches to target leukemic stem cells: Treatment-free remission as a new goal in chronic
myeloid leukemia,” Cancer Letters, vol. 347, no. 1, pp. 22–28, 2014.
[13] I. Sloma, X. Jiang, A. C. Eaves, and C. J. Eaves, “Insights into the stem cells of chronic
myeloid leukemia,” Leukemia, vol. 24, pp. 1823–33, Nov. 2010.
[14] E. Trela, S. Glowacki, and J. Blasiak, “Therapy of chronic myeloid leukemia: twilight of
the imatinib era?,” International Scholarly Research Notices Oncology, vol. 2014, pp. 1–9,
Jan. 2014.
[15] S. Branford and T. Hughes, “Detection of BCR-ABL Mutations and Resistance to Imatinib
Mesylate,” Methods in Molecular Medicine, vol. 125, pp. 93–106, Jan. 2006.
[16] O. Frank, B. Brors, A. Fabarius, L. Li, M. Haak, S. Merk, U. Schwindel, C. Zheng, M. C.
Muller, N. Gretz, R. Hehlmann, A. Hochhaus, and W. Seifarth, “Gene expression signa-
ture of primary imatinib-resistant chronic myeloid leukemia patients,” Leukemia, vol. 20,
pp. 1400–1407, May 2006.
[17] A. Hochhaus and P. La Rose´e, “Imatinib therapy in chronic myelogenous leukemia: strate-
gies to avoid and overcome resistance,” Leukemia, vol. 18, pp. 1321–31, Aug. 2004.
[18] J. J. W. M. Janssen, W. Deenik, K. G. M. Smolders, B. J. Kuijk, W. Pouwels, A. Kelder, J. J.
Cornelissen, G. J. Schuurhuis, and G. J. Ossenkoppele, “Residual normal stem cells can be
110
detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric
approach and predict for optimal response to imatinib,” Leukemia, vol. 26, pp. 977–84, May
2012.
[19] D. M. Ross, T. P. Hughes, and J. V. Melo, “Do we have to kill the last CML cell?,” Leukemia,
vol. 25, pp. 193–200, Feb. 2011.
[20] R. Jones, “Strategies to Eliminate Cancer Stem Cells,” Cancer Stem Cells, vol. 5, no. July,
pp. 219–230, 2007.
[21] N. Misaghian, G. Ligresti, L. S. Steelman, F. E. Bertrand, J. Ba¨secke, M. Libra, F. Nico-
letti, F. Stivala, M. Milella, A. Tafuri, M. Cervello, A. M. Martelli, and J. A. McCubrey,
“Targeting the leukemic stem cell: the Holy Grail of leukemia therapy,” Leukemia, vol. 23,
pp. 25–42, Jan. 2009.
[22] D. K. Hiwase, D. L. White, J. A. Powell, V. A. Saunders, S. A. Zrim, A. K. Frede, M. A.
Guthridge, A. F. Lopez, R. J. D’Andrea, L. B. To, J. V. Melo, S. Kumar, and T. P. Hughes,
“Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis
in primary CML progenitors,” Leukemia, vol. 24, pp. 771–8, Apr. 2010.
[23] Y. Chen, C. Peng, C. Sullivan, D. Li, and S. Li, “Critical molecular pathways in cancer stem
cells of chronic myeloid leukemia,” Leukemia, vol. 24, pp. 1545–54, Sept. 2010.
[24] K. Inokuchi and H. Yamaguchi, “Abnormality of c-kit oncoprotein in certain patients
with chronic myelogenous leukemia-potential clinical significance,” Leukemia, no. Octo-
ber 2001, pp. 170–177, 2002.
[25] L. K. Ashman, “The biology of stem cell factor and its receptor C-kit,” The International
Journal of Biochemistry & Bell biology, vol. 31, pp. 1037–51, Oct. 1999.
[26] F. Belloc, K. Airiau, M. Jeanneteau, M. Garcia, E. Gue´rin, E. Lippert, F. Moreau-Gaudry,
F.-X. Mahon, and E. Guerin, “The stem cell factor-c-KIT pathway must be inhibited to
enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells,”
Leukemia, vol. 23, pp. 679–685, Jan. 2009.
111
[27] K. Airiau, F.-X. Mahon, M. Josselin, M. Jeanneteau, and F. Belloc, “PI3K/mTOR pathway
inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response
of progenitors to nilotinib in the presence of stem cell factor,” Cell death & disease, vol. 4,
p. e827, Jan. 2013.
[28] J. Pande, M. M. Szewczyk, and A. K. Grover, “Phage display: concept, innovations, appli-
cations and future,” Biotechnology Advances, vol. 28, no. 6, pp. 849–58, 2010.
[29] S. Miersch and S. S. Sidhu, “Synthetic antibodies: concepts, potential and practical consid-
erations,” Methods, vol. 57, pp. 486–98, Aug. 2012.
[30] S. S. Sidhu and F. A. Fellouse, “Synthetic therapeutic antibodies,” Nature Chemical Biology,
vol. 2, pp. 682–8, Dec. 2006.
[31] W. A. Schulz, Molecular Biology of Human Cancers. Dordrecht, The Netherlands: Springer,
2007.
[32] I. Bruns, A. Czibere, J. C. Fischer, F. Roels, R.-P. Cadeddu, S. Buest, D. Bruennert, A. N.
Huenerlituerkoglu, N. H. Stoecklein, R. Singh, L. F. Zerbini, M. Ja¨ger, G. Kobbe, N. Gat-
termann, R. Kronenwett, B. Brors, and R. Haas, “The hematopoietic stem cell in chronic
phase CML is characterized by a transcriptional profile resembling normal myeloid progen-
itor cells and reflecting loss of quiescence,” Leukemia, vol. 23, pp. 892–9, May 2009.
[33] E. Diaz-Blanco, I. Bruns, F. Neumann, J. C. Fischer, T. Graef, M. Rosskopf, B. Brors,
S. Pechtel, S. Bork, A. Koch, A. Baer, U.-P. Rohr, G. Kobbe, A. von Haeseler, N. Gatter-
mann, R. Haas, and R. Kronenwett, “Molecular signature of CD34(+) hematopoietic stem
and progenitor cells of patients with CML in chronic phase,” Leukemia, vol. 21, pp. 494–
504, Mar. 2007.
[34] S. Faderl and H. Kantarjian, eds., Leukemias: Principles and Practice of Therapy. Chich-
ester, West Sussex, UK: Wiley-Blackwell, 2011.
[35] A. Lakshmikuttyamma, N. Takahashi, E. Pastural, E. Torlakovic, H. M. Amin, G. Garcia-
Manero, M. Voralia, M. Czader, J. F. DeCoteau, and C. R. Geyer, “RIZ1 is potential CML
112
tumor suppressor that is down-regulated during disease progression,” Journal of Hematol-
ogy & Oncology, vol. 2, p. 28, Jan. 2009.
[36] L. Galluzzi, L. Senovilla, L. Zitvogel, and G. Kroemer, “The secret ally: immunostimulation
by anticancer drugs,” Nature Reviews Drug Discovery, vol. 11, Feb. 2012.
[37] S. Neidle, ed., Cancer drug design and discovery. New York, NY: Academic Press, 2007.
[38] L. A. Kujawski and M. Talpaz, “The role of interferon-alpha in the treatment of chronic
myeloid leukemia,” Cytokine & Growth Factor Reviews, vol. 18, pp. 459–471, Oct. 2007.
[39] F. Guilhot, L. Roy, P.-J. Saulnier, and J. Guilhot, “Interferon in chronic myeloid leukaemia:
past and future,” Best practice & research. Clinical haematology, vol. 22, pp. 315–29, Sept.
2009.
[40] S. G. O’Brien and J. M. Goldman, “Diagnosis and Treatment of Chronic Myeloid
Leukemia,” in Neoplastic Diseases of the Blood (P. H. Wiernik, J. M. Goldman, J. P.
Dutcher, and R. A. Kyle, eds.), New York, NY: Springer New York, 2013.
[41] M. Talpaz, R. Hehlmann, A. Quinta´s-Cardama, J. Mercer, and J. Cortes, “Re-emergence of
interferon-α in the treatment of chronic myeloid leukemia,” Leukemia, vol. 27, pp. 803–12,
Apr. 2013.
[42] F. Bonifazi, A. de Vivo, G. Rosti, F. Guilhot, J. Guilhot, E. Trabacchi, R. Hehlmann,
A. Hochhaus, P. C. A. Shepherd, J. L. Steegmann, H. C. Kluin-Nelemans, J. Thaler, B. Si-
monsson, A. Louwagie, J. Reiffers, F. X. Mahon, E. Montefusco, G. Alimena, J. Hasford,
S. Richards, G. Saglio, N. Testoni, G. Martinelli, S. Tura, and M. Baccarani, “Chronic
myeloid leukemia and interferon-α: a study of complete cytogenetic responders,” Blood,
vol. 98, pp. 3074–3081, Nov. 2001.
[43] T. Schindler, W. Bornmann, P. Pellicena, and W. T. Miller, “Structural Mechanism for STI-
571 Inhibition of Abelson Tyrosine Kinase,” Science, vol. 289, pp. 1938–1942, Sept. 2000.
[44] R. T. Paniagua and W. H. Robinson, “Imatinib for the treatment of rheumatic diseases,”
Nature Clinical Practice Rheumatology, vol. 3, no. 4, pp. 190–191, 2007.
113
[45] M. J. Mauro and B. J. Druker, “STI571: Targeting BCR-ABL as Therapy for CML,” The
Oncologist, vol. 6, pp. 233–238, June 2001.
[46] C. Gambacorti-Passerini and R. Gunby, “Molecular mechanisms of resistance to imatinib in
Philadelphia-chromosome-positive leukaemias,” The Lancet Oncology, vol. 4, no. February,
pp. 75–85, 2003.
[47] A. Hochhaus, S. Kreil, A. S. Corbin, P. La Rose´e, M. C. Mu¨ller, T. Lahaye, B. Hanfstein,
C. Schoch, N. C. P. Cross, U. Berger, H. Gschaidmeier, B. J. Druker, and R. Hehlmann,
“Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy,”
Leukemia, vol. 16, pp. 2190–6, Dec. 2002.
[48] D. J. Barnes, D. Palaiologou, E. Panousopoulou, B. Schultheis, A. S. M. Yong, A. Wong,
L. Pattacini, J. M. Goldman, and J. V. Melo, “Bcr-Abl expression levels determine the rate
of development of resistance to imatinib mesylate in chronic myeloid leukemia,” Cancer
Research, vol. 65, pp. 8912–9, Oct. 2005.
[49] E. Buchdunger, C. L. Cioffi, N. Law, D. Stover, S. Ohno-jones, B. J. Druker, and N. B. Ly-
don, “Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction
Mediated by c-Kit and Platelet-Derived Growth Factor Receptors,” The Journal of Pharma-
cology and Experimental Therapeutics, vol. 295, no. 1, pp. 139–145, 2000.
[50] T. J. Abrams, L. B. Lee, L. J. Murray, N. K. Pryer, and J. M. Cherrington, “SU11248 inhibits
KIT and platelet-derived growth factor receptor beta in preclinical models of human small
cell lung cancer,” Molecular Cancer Therapeutics, vol. 2, no. May, pp. 471–478, 2003.
[51] Y. Minami, S. A. Stuart, T. Ikawa, Y. Jiang, A. Banno, I. C. Hunton, D. J. Young, T. Naoe,
C. Murre, C. H. M. Jamieson, and J. Y. J. Wang, “BCR-ABL-transformed GMP as myeloid
leukemic stem cells,” Proceedings of the National Academy of Sciences of the United States
of America, vol. 105, pp. 17967–72, Nov. 2008.
[52] E. Kavalerchik, D. Goff, and C. H. M. Jamieson, “Chronic myeloid leukemia stem cells,”
Journal of Clinical Oncology, vol. 26, pp. 2911–5, June 2008.
114
[53] M. Dean, T. Fojo, and S. Bates, “Tumour Stem Cells and Drug Resistance.,” Nature Reviews
Cancer, vol. 5, pp. 275–84, Apr. 2005.
[54] M. M. Gottesman, J. Ludwig, D. Xia, and G. Szaka´cs, “Defeating drug resistance in cancer,”
Discovery Medicine, vol. 6, pp. 18–23, Mar. 2006.
[55] M. Gorre, M. Mohammed, and K. Ellwood, “Clinical resistance to STI-571 cancer ther-
apy caused by BCR-ABL gene mutation or amplification,” Science, vol. 293, no. August,
pp. 876–880, 2001.
[56] N. J. Donato, J. Y. Wu, J. Stapley, G. Gallick, H. Lin, R. Arlinghaus, and M. Talpaz, “BCR-
ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells
selected for resistance to STI571,” Blood, vol. 101, pp. 690–698, 2003.
[57] E. Jabbour, M. Deininger, and A. Hochhaus, “Management of adverse events associated
with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia,” Leukemia,
vol. 25, pp. 201–10, Feb. 2011.
[58] F. Belloc, F. Moreau-Gaudry, M. Uhalde, L. Cazalis, M. Jeanneteau, F. Lacombe, V. Pralo-
ran, and F. Mahon, “Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia
cells through a Bim-dependant pathway modulated by cytokines,” Cancer biology & ther-
apy, vol. 6, pp. 912–9, June 2007.
[59] J. F. Apperley, J. E. Cortes, D.-W. Kim, L. Roy, G. J. Roboz, G. Rosti, E. O. Bullorsky,
E. Abruzzese, A. Hochhaus, D. Heim, C. A. de Souza, R. A. Larson, J. H. Lipton, H. J.
Khoury, H.-J. Kim, C. Sillaber, T. P. Hughes, P. Erben, J. Van Tornout, and R. M. Stone,
“Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib
failure: the START a trial,” Journal of Clinical Oncology, vol. 27, pp. 3472–9, July 2009.
[60] J. Wehrle, H. L. Pahl, and N. V. Bubnoff, “Ponatinib: A Third-Generation Inhibitor for
the Treatment of CML,” in Small Molecules in Oncology (U. M. Martens, ed.), vol. 201 of
Recent Results in Cancer Research, Berlin, Heidelberg: Springer Berlin Heidelberg, 2014.
[61] P. Bose, H. Park, J. Al-Khafaji, and S. Grant, “Strategies to circumvent the T315I gatekeeper
115
mutation in the Bcr-Abl tyrosine kinase,” Leukemia research reports, vol. 2, pp. 18–20, Jan.
2013.
[62] N. P. Shah, D. W. Kim, H. Kantarjian, P. Rousselot, P. E. D. Llacer, A. Enrico, J. Vela-Ojeda,
R. T. Silver, H. J. Khoury, M. C. Mu¨ller, A. Lambert, Y. Matloub, and A. Hochhaus, “Potent,
transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable
cytogenetic responses and high transformation-free survival rates in chronic phase chronic
myeloid leukemia patients with resistance, suboptimal response or int,” Haematologica,
vol. 95, no. 2, pp. 232–240, 2010.
[63] J. L. Snead, T. O’Hare, L. T. Adrian, C. A. Eide, T. Lange, B. J. Druker, and M. W.
Deininger, “Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis,”
Blood, vol. 114, no. 16, pp. 3459–3463, 2009.
[64] E. Weisberg, P. W. Manley, W. Breitenstein, J. Bru¨ggen, S. W. Cowan-Jacob, A. Ray,
B. Huntly, D. Fabbro, G. Fendrich, E. Hall-Meyers, A. L. Kung, J. Mestan, G. Q. Daley,
L. Callahan, L. Catley, C. Cavazza, M. Azam, A. Mohammed, D. Neuberg, R. D. Wright,
D. G. Gilliland, and J. D. Griffin, “Characterization of AMN107, a selective inhibitor of
native and mutant Bcr-Abl,” Cancer Cell, vol. 7, pp. 129–41, Feb. 2005.
[65] E. Weisberg, P. W. Manley, S. W. Cowan-Jacob, A. Hochhaus, and J. D. Griffin, “Second
generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid
leukaemia,” Cancer, vol. 7, pp. 345–56, May 2007.
[66] T. O’Hare, M. S. Zabriskie, A. M. Eiring, and M. W. Deininger, “Pushing the limits of
targeted therapy in chronic myeloid leukaemia,” Nature reviews. Cancer, vol. 12, pp. 513–
26, Aug. 2012.
[67] E. Weisberg, P. Manley, J. Mestan, S. Cowan-Jacob, A. Ray, and J. D. Griffin, “AMN107
(nilotinib): a novel and selective inhibitor of BCR-ABL,” British Journal of Cancer, vol. 94,
pp. 1765–9, June 2006.
[68] S. M. Graham, H. G. Jorgensen, E. Allan, and C. Pearson, “Primitive, quiescent,
116
Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive
to STI571 in vitro,” Blood, vol. 99, pp. 319–325, Jan. 2002.
[69] N. N. Bewry, R. R. Nair, M. F. Emmons, D. Boulware, J. Pinilla-Ibarz, and L. A. Hazlehurst,
“Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvi-
ronment model of drug resistance,” Molecular Cancer Therapeutics, vol. 7, pp. 3169–75,
Oct. 2008.
[70] E. Weisberg, R. D. Wright, D. W. McMillin, C. Mitsiades, A. Ray, R. Barrett, S. Adamia,
R. Stone, I. Galinsky, A. L. Kung, and J. D. Griffin, “Stromal-mediated protection of ty-
rosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells,” Molecular Cancer
Therapeutics, vol. 7, pp. 1121–9, May 2008.
[71] R. R. Nair, J. H. Tolentino, R. F. Argilagos, L. Zhang, J. Pinilla-Ibarz, and L. A. Hazlehurst,
“Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microen-
vironment requires a promiscuous JAK inhibitor in CML,” Leukemia Research, vol. 36,
pp. 756–63, June 2012.
[72] K. L. Sweet, L. A. Hazlehurst, and J. Pinilla-Ibarz, “The one-two punch: combination treat-
ment in chronic myeloid leukemia,” Oncology Hematology, vol. 88, pp. 667–79, Dec. 2013.
[73] C. T. Jordan, “The leukemic stem cell,” Best Practice and Research in Clinical Haematol-
ogy, vol. 20, no. 1, pp. 13–18, 2007.
[74] R. Di Noto, C. L. Lo Pardo, E. M. Schiavone, C. Manzo, and C. Vacca, “Stem cell factor re-
ceptor (c-kit, CD117) is expressed on blast cells from most immature types of acute myeloid
malignancies but is also a characteristic of a subset of acute promyelocytic leukaemia,”
British Journal of Haematology, pp. 562–564, 1996.
[75] V. A. Dolgachev, M. R. Ullenbruch, N. W. Lukacs, and S. H. Phan, “Role of stem cell
factor and bone marrow-derived fibroblasts in airway remodeling,” The American Journal
of Pathology, vol. 174, pp. 390–400, Mar. 2009.
[76] J. Lennartsson and L. Ro¨nnstrand, “The stem cell factor receptor/c-Kit as a drug target in
cancer,” Current cancer drug targets, vol. 6, pp. 65–75, Feb. 2006.
117
[77] H. Liu, X. Chen, P. J. Focia, and X. He, “Structural basis for stem cell factor-KIT signaling
and activation of class III receptor tyrosine kinases,” The EMBO journal, vol. 26, pp. 891–
901, Feb. 2007.
[78] L. Ronnstrand, “Signal transduction via the stem cell factor receptor/c-Kit,” Cellular and
Molecular Life Sciences: CMLS, vol. 61, pp. 2535–48, Oct. 2004.
[79] A. Q. Shen, N. M. Wilson, S. L. Gleason, and H. J. Khoury, “Bosutinib in the treatment of
patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an
overview,” Therapeutic Advances in Hematology, vol. 5, pp. 13–7, Mar. 2014.
[80] S. J. Neering, T. Bushnell, S. Sozer, J. Ashton, R. M. Rossi, P.-Y. Wang, D. R. Bell, D. Hein-
rich, A. Bottaro, and C. T. Jordan, “Leukemia stem cells in a genetically defined murine
model of blast-crisis CML,” Blood, vol. 110, pp. 2578–85, Oct. 2007.
[81] P. Besmer, J. E. Murphy, P. C. George, F. H. Qiu, P. J. Bergold, L. Lederman, H. W. Snyder,
D. Brodeur, E. E. Zuckerman, and W. D. Hardy, “A new acute transforming feline retrovirus
and relationship of its oncogene v-kit with the protein kinase gene family,” Nature, vol. 320,
pp. 415–21, 1986.
[82] R. Roskoski, “Signaling by Kit protein-tyrosine kinase - the stem cell factor receptor,” Bio-
chemical and biophysical research communications, vol. 337, pp. 1–13, 2005.
[83] S. Yuzawa, Y. Opatowsky, Z. Zhang, V. Mandiyan, I. Lax, and J. Schlessinger, “Structural
basis for activation of the receptor tyrosine kinase KIT by stem cell factor,” Cell, vol. 130,
pp. 323–34, July 2007.
[84] F. Xiang, X. Lu, L. Hammoud, P. Zhu, P. Chidiac, J. Robbins, and Q. Feng, “Cardiomyocyte-
specific overexpression of human stem cell factor improves cardiac function and survival
after myocardial infarction in mice,” Circulation, vol. 120, pp. 1065–74, 9 p following 1074,
Sept. 2009.
[85] P. T. Went, S. Dirnhofer, M. Bundi, M. Mirlacher, P. Schraml, S. Mangialaio, S. Dimitrijevic,
J. Kononen, A. Lugli, R. Simon, and G. Sauter, “Prevalence of KIT expression in human
tumors,” Journal of Clinical Oncology, vol. 22, pp. 4514–22, Nov. 2004.
118
[86] B. P. Rubin, S. Singer, C. Tsao, A. Duensing, M. L. Lux, R. Ruiz, M. K. Hibbard, C.-
j. Chen, S. Xiao, D. A. Tuveson, G. D. Demetri, C. D. M. Fletcher, and J. A. Fletcher,
“KIT Activation Is a Ubiquitous Feature of Gastrointestinal Stromal Tumors,” American
Association for Cancer Research, pp. 8118–8121, 2001.
[87] A. Beghini, L. Larizza, R. Cairoli, and E. Morra, “C-Kit Activating Mutations and Mast
Cell Proliferation in Human Leukemia,” Blood, vol. 92, pp. 701–2, July 1998.
[88] A. S. Corbin, T. O’Hare, Z. Gu, I. L. Kraft, A. M. Eiring, J. S. Khorashad, A. D. Pomicter,
T. Y. Zhang, C. A. Eide, P. W. Manley, J. E. Cortes, B. J. Druker, and M. W. Deininger,
“KIT signaling governs differential sensitivity of mature and primitive CML progenitors to
tyrosine kinase inhibitors,” Cancer research, vol. 73, pp. 5775–86, Sept. 2013.
[89] F. Nwajei and M. Konopleva, “The bone marrow microenvironment as niche retreats for
hematopoietic and leukemic stem cells,” Advances in hematology, pp. 1–8, Jan. 2013.
[90] E. A. Grimm, “Cytokines: Biology and Applications in Cancer Medicine,” in Holland-Frei
Cancer Medicine (R. C. Bast and J. F. Holland, eds.), Shelton, CT: PMPH USA, 8th ed.,
2010.
[91] D. Kalderon, “Signaling Pathways in Cancer,” in Principles of Molecular Oncology (M. H.
Bronchud and E. al, eds.), ch. 8, pp. 153–188, Totowa, NJ: Humana Press, 2008.
[92] J. Liang, Y. Wu, B.-J. Chen, W. Zhang, Y. Tanaka, and H. Sugiyama, “The C-kit receptor-
mediated signal transduction and tumor-related diseases,” International journal of biologi-
cal sciences, vol. 9, pp. 435–43, Jan. 2013.
[93] J. Schlessinger, “Cell Signaling by Receptor Tyrosine Kinases,” Cell, vol. 103, pp. 211–225,
2000.
[94] M. A. Lemmon and J. Schlessinger, “Cell signaling by receptor tyrosine kinases.,” Cell,
vol. 141, pp. 1117–34, June 2010.
[95] C. V. Lee, W.-C. Liang, M. S. Dennis, C. Eigenbrot, S. S. Sidhu, and G. Fuh, “High-affinity
human antibodies from phage-displayed synthetic Fab libraries with a single framework
scaffold,” Journal of Molecular Biology, vol. 340, pp. 1073–93, July 2004.
119
[96] R. K. Oldham and R. O. Dillman, “Monoclonal antibodies in cancer therapy: 25 years of
progress,” Journal of Clinical Oncology, vol. 26, pp. 1774–7, Apr. 2008.
[97] R. Kontermann, ed., Bispecific Antibodies. Heidelberg, Germany: Springer, 2011.
[98] I. Benhar, “Design of synthetic antibody libraries,” Expert Opinion on Biological Therapy,
vol. 7, no. 5, pp. 763–779, 2007.
[99] G. Hardiman, “Next-generation antibody discovery platforms,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 109, pp. 18245–6, Nov. 2012.
[100] B. Nelson and S. S. Sidhu, “Synthetic Antibody Libraries,” vol. 899, pp. 27–41, 2012.
[101] M. Silacci, S. Brack, G. Schirru, J. Marlind, A. Ettorre, A. Merlo, F. Viti, and D. Neri, “De-
sign, construction, and characterization of a large synthetic human antibody phage display
library,” Proteomics, vol. 5, pp. 2340–2350, June 2005.
[102] F. A. Fellouse and S. S. Sidhu, “Synthetic Antibody Libraries,” in Phage Display in Drug
Discovery and Biotechnology (S. S. Sidhu, ed.), pp. 709–740, Boca Raton, FL: CRC Press,
2005.
[103] J. Krauss, “Application of recombinant antibodies in cancer patients,” in Recombinant an-
tibodies for cancer therapy: methods and protocols (M. Welschof and J. Krauss, eds.),
vol. 207, ch. 2, pp. 4–27, Totowa, N.J: Humana Press Inc, 1st ed., 2003.
[104] C. R. Geyer, J. McCafferty, S. Du¨bel, A. R. M. Bradbury, and S. S. Sidhu, “Recombinant
antibodies and in vitro selection technologies,” in Methods in molecular biology (G. Proetzel
and H. Ebersbach, eds.), vol. 901, ch. 2, pp. 11–32, Jan. 2012.
[105] S. M. Deyev and E. N. Lebedenko, “Modern Technologies for Creating Synthetic Antibodies
for Clinical application,” Acta naturae, vol. 1, pp. 32–50, Apr. 2009.
[106] M. S. Dennis, “Selection and screening strategies,” in Phage Display in Drug Discovery and
Biotechnology (S. S. Sidhu, ed.), ch. 4, pp. 143–161, Boca Raton, FL: CRC Press, 2005.
[107] ForteBIO, Octet System - User’s Guide. ForteBIO, Inc., 2011.
120
[108] M. S. Silberberg, Chemistry: the molecular nature of matter and change. Boston, MA:
McGraw-Hil, 6 ed., 2012.
[109] J. P. Landry, Y. Fei, and X. Zhu, “Simultaneous measurement of 10,000 protein-ligand affin-
ity constants using microarray-based kinetic constant assays,” Assay and drug development
technologies, vol. 10, pp. 250–9, June 2012.
[110] Y. Sun, J. Landry, Y. Fei, X. Zhu, and J. Luo, “Effect of Fluorescently Labeling Protein
Probes on Kinetics of Protein-Ligand Reactions,” Langmuir, vol. 24, no. 23, pp. 13399–
13405, 2008.
[111] J. Landry, Y. Fei, and X. Zhu, “High Throughput, Label-free Screening Small Molecule
Compound Libraries for Protein-Ligands using Combination of Small Molecule Microar-
rays and a Special Ellipsometry-based Optical Scanner,” International Drug Discovery,
pp. 8–13, 2011.
[112] Y. S. Sun, J. P. Landry, Y. Fei, and X. Zhu, “an Oblique-Incidence Reflectivity Difference
Study of the Dependence of Probe-Target Reaction Constants on Surface Target Density
Using Streptavidin-Biotin Reactions As a Model,” Instrumentation Science & Technology,
vol. 41, pp. 535–544, Sept. 2013.
[113] G. Mor and A. Alvero, Apoptosis and Cancer: Methods and Protocols. Totowa, NJ: Humana
Press, 2008.
[114] M. Sluyser, Application of apoptosis to cancer treatment. Dordrecht, The Netherlands:
Springer, 2005.
[115] D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144,
pp. 646–74, Mar. 2011.
[116] R. A. Weinberg, The Biology of Cancer. New York: Garland Science, 2007.
[117] A. S. M. Yong, K. Keyvanfar, R. Eniafe, B. N. Savani, K. Rezvani, E. M. Sloand, J. M.
Goldman, and a. J. Barrett, “Hematopoietic stem cells and progenitors of chronic myeloid
leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia
121
effect and peptide vaccine-based immunotherapy,” Leukemia, vol. 22, pp. 1721–7, Sept.
2008.
[118] J. F. Dorsey, J. M. Cunnick, R. Lanehart, M. Huang, a. J. Kraker, K. N. Bhalla, R. Jove,
and J. Wu, “Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from
apoptosis induced by Bcr-Abl tyrosine kinase inhibitors,” Leukemia, vol. 16, pp. 1589–95,
Sept. 2002.
[119] A. Lakshmikuttyamma, E. Pastural, N. Takahashi, K. Sawada, D. P. Sheridan, J. F. De-
Coteau, and C. R. Geyer, “Bcr-Abl induces autocrine IGF-1 signaling,” Oncogene, vol. 27,
pp. 3831–44, June 2008.
[120] R. G. Maki, “Small is beautiful: insulin-like growth factors and their role in growth, devel-
opment, and cancer,” Journal of Clinical Oncology, vol. 28, pp. 4985–95, Nov. 2010.
122
